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ABSTRACT 
Christina D. Fitch.  THE SERINE PROTEASE FROM THE VENOM OF POLISTES 
DOMINULUS CONTAINS ALLERGENIC EPITOPES.  (Under the direction of Dr. 
Donald R. Hoffman)  Interdisciplinary Program in Biological Sciences, East Carolina 
University, April 2010. 
 
  The protection introduced by immunotherapy to patients with allergies to paper 
wasps may be partial depending on the sensitizing species.  Partial cross-reactivity 
between major paper wasp groups may be the reason for partial protection.   
Understanding patient response to venom allergens from the paper wasp groups is 
important to improve and develop effective treatments.  Research has shown that the 
allergenic serine protease may be important in this partial cross-reactivity.  In this study 
we investigated the importance of epitopes on the allergenic serine protease (Pol d 4) 
from Polistes dominulus.  Recombinant Pol d 4 was expressed in prokaryotic and 
eukaryotic expression systems.  The expression products from the eukaryotic system 
yielded a protein of larger size than predicted size.  Two constructs of Pol d 4 were 
produced in the prokaryotic expression system and were of expected size.   Re-folding 
of the prokaryotic expressed recombinant proteins was not successful.  The major 
amino acid epitopes on Pol d 4 were predicted.  Three mutant constructs were chosen, 
each containing two amino acid substitutions within a predicted epitopes.  IgE binding 
was assayed by immunoblot assays using sera from European and North American 
patients. The majority of European patient sera had IgE that bound to the recombinant 
form of Pol d 4.   Statistical analysis showed that there was no significant difference in 
IgE binding to the various proteins.  IgE from American patients bound recombinant 
Pol d 4.  Bromelain was used in immunoblot inhibition to assay possible carbohydrate 
epitopes.  The inhibition assay showed evidence of IgE binding.  The serine protease 
 ii 
from Polistes gallicus was characterized.  Identity between the two serine proteases was 
high. Evidence supports the presence of carbohydrate on the recombinant protease and  
carbohydrate epitopes may be present.  Visually, all three mutant proteins bound IgE; 
mutant 2 bound IgE from the least number of patients suggesting it may be an 
important epitope on Pol d 4.  Analysis of densitometric data showed no significant 
difference between the proteins tested. The data suggests that there may be amino acid 
epitopes present.  Further, the high sequence identity between Pol d 4 and Pol g 4 
support high cross-reactivity between sister species.   
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Chapter 1:  INTRODUCTION 
 Allergies affect the lives of millions of Americans (Stempel, 1997).  In the United 
States it is estimated that 50 million individuals suffer from allergic diseases (Gergen et 
al., 1987).  These numbers make allergies the fifth most prevalent chronic disease in 
adults and the third most common in children under the age of 18 (National Academy, 
2000).  Approximately 55% of the population has positive skin tests to insect venom 
(Arbes et al., 2005).  An anaphylactic reaction occurs in 0.5 to 5% of all individuals 
allergic to insect venom proteins and causes an estimated 40 deaths per year in the United 
States (Valentine, 1992). The immunologic reaction to venom protein may be species 
specific or cross-reactive with homologous proteins of various insect genera.  Increasing 
our understanding of the complex interactions between venom proteins and the immune 
system will aid in improving patient treatment and care.  
 The stinging insects that are responsible are the medically important species of 
the order Hymenoptera, which includes bees, wasps and ants.  Paper wasps, belonging to 
the genus Polistes, are separated into groups based on subgenera and geographic location 
(Pickett and Wenzel, 2004).  Testing has shown that the cross-reactivity between 
different paper wasp subgenera is partial (Pantera et al., 2003 and Hoffman et al., 1990), 
while cross-reactivity among members within each group is strong.  The partial cross-
reactivity observed among the paper wasp groups may have an impact on testing and 
treatment of paper wasp allergies.  The allergens present in paper wasp venom have been 
identified and several have been characterized.  Studies with venom serine protease have 
shown that this allergen may play a role in species-specific immunogenic reactivity.  
Here, the major allergens found in Polistes venom will be discussed in regards to cross-
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reactivity, and an examination of the role that the allergic serine protease plays in 
species-specific IgE reactivity will be investigated.   
1.1 Allergens 
An anaphylactic reaction was initially reported in dogs reacting to sea anemone 
toxin by Richet and Portier in 1902.  The same reaction was later described in humans 
against horse serum. Clemons von Pirquet hypothesized that immunity and 
hypersensitivity reactions would depend on interactions between the human immune 
system and a foreign substance (Von Pirquet, 1906).  These foreign substances would 
later be identified as antigens and the interaction was mediated by IgE antibody.  
Antigens that elicit a clinical allergic reaction are typically referred to as allergens.   
Interaction between IgE and an allergen causes a cascade of events, which can 
manifest as a type I hypersensitive or allergic reaction in sensitized individuals.   IgE is 
bound to the surface of effector cells, mast cells and basophils, and the interaction with 
an allergen causes the release of physiologic mediators.  These mediators cause the 
various physical manifestations (Grammer and Greenberger, 2002).  Allergens are 
typically proteins containing post-translational carbohydrates and can be derived from a 
variety of sources.  Insect allergens are introduced to humans by two main routes.  The 
first pathway is inhalation, and this type of allergen is associated with asthmatic attacks 
in sensitized individuals (Bernton, et al., 1970 and Kang et al., 1979).  The alternate route 
is introduction of the allergen by dermal injection of venom proteins by insects from the 
order Hymenoptera.    
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1.2  Epitopes 
 Binding of IgE is specific for a particular portion of an allergen, referred to as an 
epitope.   Structurally, epitopes can either be conformational or linear.  Conformational 
epitopes consist of amino acids which are in close proximity while the protein is folded 
correctly but are found on multiple regions of the primary structure.  Linear epitopes are 
amino acids sequentially located on the primary structure. Most allergenic epitopes are  
conformational.  Food allergens consist of both types; linear epitopes are produced during 
digestion of food products before they interact with the immune system.  In insect 
allergies, interaction of the epitopes with IgE relies heavily on the conformation of the 
allergen.  Therefore, amino acid residues within a particular epitope may span the entire 
length of the molecule, with the possibility of larger proteins containing multiple epitopes 
(Kurup et al., 1998, Rabjohn et al., 1999, Furmonavicience et al., 2000, and Ramos et al., 
2003).  Cross-reactivity is the recognition of similar or identical epitopes on proteins 
from different sources.  The presence of cross-reactive epitopes complicates the study 
and understanding of IgE binding to these proteins.   
 Clinically, cross-reactive epitopes make identification of the sensitizing species 
difficult.  The presence of the cross-reactive epitopes can make a patient appear allergic 
to an insect venom protein they have not encountered because of structural homology.  
Treatment of insect allergies requires the identification of the sensitizing species.  Errors 
in identification of the species could lead to incomplete or partial protection of the patient 
during treatment.   
 Cross-reactivity between homologous allergens includes both the recognition of 
IgE to amino acid and carbohydrate portions of the protein.  Characterization of the 
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amino acid sequence of various venom proteins has allowed researchers to identify 
possible homologous cross-reactive allergens.  The ability of insect allergens with high 
sequence identity to cross-react has been extensively documented. The general trend 
follows that as the sequence homology drops between two allergens, so does the degree 
of cross-reactivity.  This trend is so strong with some allergens that the degree of cross-
reactivity decreases as the phylogenetic distance between the insects increases (Hoffman, 
1993).   
 In addition to the amino acid sequence, cross-reactivity has been observed by IgE 
binding to post-translational carbohydrates on venom proteins.  Detectable cross-
reactivity between various allergens that lack high amino acid sequence identity can be 
explained in part by the presence of N-linked carbohydrate groups called cross-reactivity 
carbohydrate determinants (CCD), shown in Figure 1.
 
 First identified in plants and insect 
glycoproteins, these epitopes typically consist of a 1,3 fucose core (Bencurova, 2004 and 
Chunsheng, 2008).  Research has shown that the CCD has the ability to be a major factor 
in cross-reactivity between highly diverse groups of glycoproteins from insect and plant 
sources (Hemmer et al., 2001, Hemmer et al., 2004, and Bencurova et al., 2004).  The 
presence CCD-specific IgE makes identification of sensitizing species difficult.  
Additional studies have suggested that CCD-specific IgE lack or have very limited 
capacity to elicit a clinical response in sensitized patients. 
 1.3 The Order Hymenoptera 
 The medically important members of the order Hymenoptera can deliver venom 
allergens by subcutaneous injection.  This diverse order includes three major families of 
social stinging insects; major allergens have been identified and characterized in 
 5 
 
 
 
 
 
 
 
 
 
 
Figure 1:  The structure of a CCD epitope.  The CCD is a 6-sugar chain liked to an 
asparagine (A).  The chain includes two N-acetyl-glucosamines (G), two mannose (M), 
one 1,3-fucose (F) and a 1,2-xylose (X) (Malandain, 2005).     
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several species groups within these families.  These families are: Apidae (honey bees and 
bumble bees), Vespidae (wasps, hornets, and yellow jackets), and Formicidae (ants) 
(Figure 2) (Pickett and Wenzel, 2004).   
The medically important apids contain two major genera: Apis (honey bees) and 
Bombus (bumble bees) (Figure 2).  Members of this family are found worldwide in 
diverse locations.  This family has been of particular interest because of their agricultural 
impact.  This family of insects is an economic resource and the occupational hazards that 
stem from working with members of this group are of great interest.   
The members of the family Formicidae are commonly referred to as ants (Figure 
2).  The majority of venom allergens characterized from this family have been from 
members of the genus Solenopsis.  The Solenopsis ants are found in diverse locations 
including North America, South America, and islands in South East Asia.  Two medically 
important species S. richteri and S. invicta inhabit the United States.  In addition to 
Solenopsis, allergy inducing members of Formicidae includes the Myrmecia and 
Pachycondyla genera.  Myrmecia ants are large primitive ants indigenous to Australia.  
Pachycondyla include ants from Eastern and Western Asia and now found in the United 
States.    
 The medically important Vespids are comprised of four genera (Figure 2) which 
are found in various geographic locations worldwide.  The yellow jackets are grouped 
into the genus Vespula.  The various types of hornets are divided into two genera.  The 
first genus, Dolichovespula, includes hornet species, such as Yellow and White faced 
hornets.  The second genus, Vespa, includes European and Mandarin hornets. The last  
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Figure 2:  The medically important Hymenoptera phylogenic tree.  The three major 
allergy causing families of the Order Hymenoptera are shown.  The family Apidae (honey 
bees and bumble bees) contains the Apis and Bombus genera.  The Formicidae (ants) 
contains three genera: Solenopsis, Myrmecia, and Pachycondyla.  The Vespids (wasps, 
hornets, and yellow jackets) include four genera; Vespula, Vespa, Dolichovespula, and 
Polistes.  Genus Polistes is further broken down into two groups, Old World and New 
World paper wasps.  Old World paper wasps include the subgenus Polistes.  New World 
paper wasps are composed of two subgenera Fuscopolistes and Aphanilopterus.  
Common species of paper wasps are listed for each group.  Note, distance between 
groups does not denote evolutionary distance.   
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Vespid genus is Polistes; members of this genus are commonly referred to as paper or 
umbrella wasps. 
1.4  Polistes   
Paper wasps are generally classified into two groups based on geographic origin 
and subgenus (Figure 2).  The first group of paper wasps is New World paper wasps.  
Members of this group are indigenous to North America.  The major allergy-inducing 
North American paper wasps are represented by two subgenera: Fuscopolistes, 
represented by Polistes fuscatus, and Aphanilopterus, which includes two common New 
World paper wasp species, Polistes exclamans and Polistes annularis.  The second major 
group of paper wasps is Old World paper wasps.  These insects are indigenous to Europe 
and parts of Asia and Africa.  European and North African paper wasps have one major 
subgenus, Polistes.  This subgenus contains two common species, Polistes dominulus and 
Polistes gallicus (Pickett and Wenzel, 2004).  Since the 1970’s Polistes dominulus has 
established itself in the Northeastern part of North America. 
1.5 Hymenoptera venom  
The venom from medically important Hymenoptera insects contains a wide 
variety of proteins and chemicals with various pharmacological activities.  The various 
components of the venom are intended as a defense mechanism for wasps. The allergic 
reaction is not intended and does not occur against all venom proteins.  The biological 
purpose for many of these components has been identified, while the function of others 
has not been resolved.   
 11 
Formicid venom composition differs from the venom of other Hymenoptera.  Fire 
ant venom is comprised mainly of alkyl and alkenyl piperidine alkaloids (MacConnell et 
al., 1974); these components are responsible for the characteristic sterile pustule that 
results following injection of venom (deShazo et al., 1984 and Javors et al., 1993).  The 
allergic reaction from fire ant venom is the result of patient IgE interaction with the small 
amount of proteins present in the venom.  Four major allergens have been characterized 
in fire ant venom: phospholipase A1B (Hoffman et al., 1988 and Hoffman et al., 2005), a 
13.3 kDa protein dimer (Hoffman et al., 1988, Hoffman et al., 1990, Hoffman, 1993, 
Schmidt et al., 1993, Schmidt et al., 1996, and Hoffman, 1997), Antigen 5 (Hoffman et 
al., 1988, Hoffman et al., 1990, Hoffman, 1993, Hoffman, 1997, and Schmidt et al., 
2003), and an allergen of unknown function  (Hoffman et al., 1988, Hoffman, 1993, and 
Hoffman, 1997) (Table 1).  
Apid and Vespid venom have similar compositions.  The venom components are 
grouped into three types of molecules: low molecular weight substances, peptides, and 
high molecular weight substances (Meier, 1995).  The low molecular weight substances 
include a variety of compounds, such as pheromones, histamine, and serotonin.  
Histamine makes up a substantial portion of the venom and is one of the major 
components that facilitate the pain response (Mueller, 1990 and Meir, 1995).  Peptides, 
including kinins, also contribute to the pain response. In addition, various peptides have 
shown characteristics that aid in the degranulation of mast cells (Meier, 1995).  High  
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Table 1:  List of the major allergens associated with the order Hymenoptera.  The  
major allergens that have been identified in Apids, Formicids, and Vespids are shown.  
Honeybee venom contains hyaluronidase, melittin, phospholipase A2, an allergenic serine 
protease, a 13 kDa allergen, and an unknown allergen.  Formicid venom contains Antigen 
5 and Phospholipase A1B.  Vespid venom contains Antigen 5, phospholipase A1B, and 
hyaluronidase.  Paper wasp venoms also contain an allergenic serine protease. 
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Apids Formicids                  Vespids
AbsentAbsentPresentOther allergen
Present in paper 
wasps
AbsentPresentSerine Protease
AbsentAbsentPresent13 kDa Allergen
PresentAbsentPresentHyaluronidase
AbsentAbsentPresentMelittin
Present, A2BPresent, A2BPresent, A2Phospholipase
PresentPresentPresentAntigen 5
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molecular weight molecules include a wide variety of proteins, encompassing the 
majority of enzymes, and contain the major venom allergens (Meir, 1995).  
Although the venom composition of Apids is similar to that of the Vespids, the 
major allergens differ.  Honey bees have four identified major allergens:  Phospholipase 
A2, (King et al., 1976, Hoffman and Shipman, 1976, Kuchler et al., 1989 Hoffman and 
Schmidt, 2000 and Li et al., 2005), Hyaluronidase (Hoffman, 2006, and Shen et al.,  
2002), Melittin (Habermann et al., 1967, Paull et al., 1977, and Shi et al., 2003), and a 
CUB Serine Protease (Jeep et al., 1996, Kettner et al., 1999, Wood and Hoffman, 1983, 
Winningham et al., 2004) (Table 1).  The allergens identified in bumble bee venom differ 
from those found in honey bees.  Their venom only contains two major allergens: 
Phospholipase A2 (Hoffman and Jacobson, 1996) and a serine protease (Hoffman and 
Jacobson, 1996).  The phospholipases found in honey bees and bumble bees are similar 
(de Groot et al., 1995), however, the serine protease does not cross-react between 
honeybees and bumble bees (Winningham et al., 2004).   
1.6  Vespid venom allergens  
 Venom allergens isolated from Vespids have been extensively studied from a 
wide variety of these insects found worldwide.   A general trend in cross-reactivity is 
seen when the venoms of these animals are compared.   Hornet and yellow jacket venom 
are partially cross-reactive with one another.  The cross-reactivity decreases when the 
venom allergen from either hornets or yellow jackets is compared to homologous 
allergens from paper wasp venom.  It has been reported that venom of paper wasps within 
the two major groups is partially cross-reactive, suggesting unique epitopes among the 
allergens of each group.   Three major allergens have been identified in the venom of all 
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Vespids: Antigen 5 (Fang et al., 1987, Hoffman et al., 1988, Lu et al., 1993, Hoffman, 
1993, Hoffman and Schmidt, 1999, Pirpignani et al., 2002, Pantera et al., 2003, and  
Fitch et al., 2006), Phospholipase A1B (King et al., 1984, Soldatova et al., 1993, 
Hoffman, 1994, Henriksen et al., 2001, Pantera et al., 2003, Hoffman et al., 2005, 
Moawad et al., 2005, and Fitch et al., 2006), and Hyaluronidase (King  et al., 1984, Lu et 
al., 1995, King et al., 1996, and Kolarich et al., 2005). A fourth allergen, a trypsin-like 
serine protease, has been isolated from the venom of Polistes wasps (Pantera et al., 2003, 
Winningham et al., 2004, and Fitch et al., 2006).  
1.6.1 Antigen 5 
  The Antigen 5 is one of the most important allergens in yellow jacket and hornet 
venoms in terms of IgE binding (King and Spangfort, 2000, King and Guralnick, 2004, 
and Hoffman, 2006).   Antigen 5 typically ranges in size from 201-212 amino acids and 
does not appear to be glycosylated (King et al., 1978, Hoffman and McDonald, 1982, 
Fang et al., 1988, and Hoffman and Schmidt, 1999).  This protein accounts for 
approximately 5-10% of the dry weight of the venom (Mueller, 1990).  Members of the 
Antigen 5 family have been found in most eukaryotic organisms and have been 
characterized in several insect species.  Other members of this family are involved in 
plant pathogenesis (King et al., 1990), sexual maturation (Hawdon et al., 1996), lizard 
venom protein (Morrisette et al., 1995), and tumor-related proteins in humans (Rich et 
al., 1996 and Hoffman, 2008).  The Antigen 5 allergen shows homology with a 
neurotoxin found in the Asian hornet V. mandarinia.  However, assays have shown that 
venom Antigen 5 allergen does not have synaptic toxin activity. Antigen 5 allergen is a 
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highly conserved molecule in insects; however the biological function in the venom is 
still not known (King et al., 1984, Hoffman and Schmidt, 1999).    
Antigen 5 from P. exclamans and P. annularis (New World paper wasps) were 
analyzed for sequence identity and cross-reactivity with Antigen 5 from hornets (D. 
arenaria and D. maculata) and yellow jackets (V. maculifrons and V. vulgaris).  The 
Antigen 5 from hornet and yellow jacket venom showed a high degree of cross-reactivity.  
When cross-reactivity between Antigen 5 proteins from hornets or yellow jackets were 
compared to the homologous allergen isolated from paper wasp venom, the amount of 
cross-reactivity decreased to approximately 60% (Hoffman, 1993 and Hoffman, 1997).  
Comparison ofAntigen 5 from European paper wasps and Formicid venom showed 48% 
identity (Hoffman et al., 1988, Hoffman, 1993, Schmidt et al., 2003, and Pantera, 2003).  
The identity of the Antigen 5 found in venom from P. dominulus and P. gallicus, 
European paper wasps, is high at approximately 98% (Lu et al., 1993 and Pantera et al., 
2003).  Identity between Antigen 5 from the New World Polistes and Old World paper 
wasps decreases to 85%. The cysteine residues within Antigen 5 are conserved, 
suggesting a high degree of structural similarity between molecules from different insect 
groups (Hoffman and McDonald, 1982, Hoffman, 1985, and Hoffman, 1993).  Identity 
between Old World paper wasps venom allergens and Hymenopteran venom allergens 
are shown in Table 2. 
1.6.2 Phospholipase A1B 
 Phospholipase A1B identified in Vespid venom has the ability to significantly 
bind IgE.  This 42 kDa protein is a member of the lipoprotein lipase superfamily 
(Hoffman, 2008).  This family is responsible for the cleavage of the fatty acid from the 1-  
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Table 2: Comparison of percent identity between P. dominulus venom allergens and 
the common Hymenopteran insect allergens.  P. dominulus Antigen 5 shared the most 
identity with the Antigen 5 from the New World paper wasps and the least with the 
Formicids.  The Hyaluronidase sequence from P. dominulus has not been identified; 
therefore a comparison could not be made.  The Phospholipase A1B allergen shared the 
most identity with the homologous molecule from the New World paper wasps and the 
least with the Formicids.  The serine protease allergen sequence from the New World 
paper wasp could not be characterized.  The serine protease isolated from honey bees 
shows the highest identity, and the lowest when compared to that from bumble bees. 
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position of phospholipids, followed by cleavage of the fatty acid in the 2-position.  This 
enzyme differs from the allergenic phospholipase in Apids, which is a Phospholipase A2 
(King et al., 1978, King et al., 1983, Hoffman, 1985, and Hoffman, 1994). Cross- 
reactivity between homologous Phospholipase A1B allergens in various insect species 
typically correlates with predicted phylogeny (Hoffman, 1981, Hoffman and McDonald, 
1982, Hoffman, 1985, and Hoffman, 1986).  The phospholipase A1B allergen from 
hornets and wasps show 47-52% identity when compared to the New World paper wasp 
allergen.  The Formicid Phospholipase A1B has 33% identity.  This allergen has been 
isolated and characterized from P. dominulus (Pol d 1) and P. annularis (Pol a 1) 
(Moawad, 2005 and King et al., 1984), and a partial amino acid sequence for P. gallicus 
(Pol g 1) phospholipase has been reported (Pantera et al., 2003).  Comparison of these 
amino acid sequences show that Pol g 1, amino acids 1-41, and the derived sequence for 
Pol d 1 have 95% identity.   The identity decreases to 75.4% when Pol d 1 is compared 
with Pol a 1.  
1.6.3 Hyaluronidase 
 Venom hyaluronidase has been identified as a significant allergen in Vespid 
venom.  This 42 kDa protein (King et al., 1984, Lu et al., 1995, King et al., 1996, and 
Kolarich et al., 2005) is responsible for hydrolyzing hyaluronic acid, an important 
component of the extracellular matrix.  This cleavage may facilitate the movement of 
other venom components through the skin. 
 The hyaluronidase allergen has been isolated and characterized in various insect 
species, including yellow jackets, hornets, paper wasps and honey bees. Reports suggest 
that the presence of N-linked carbohydrates (Hoffman, 1994).  Sequence identity between 
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yellow jacket and hornet hyaluronidase is approximately 91.5% (King et al., 1996). 
When compared to hyaluronidase from the paper wasp species, the percent identity 
decreases to approximately 75% (Pantera 2003).  The homologous molecule from honey 
bees has approximately 50% identity with the Vespids.  Cross-reactivity has been 
reported observed between hyaluronidase from various stinging insects. These studies 
have shown that high sequence identity is not required for cross-reactivity between 
hyaluronidase allergen and suggests the cross-reactivity may be due to post-translational 
glycosylation (Jacobson et al., 1992 and Lu et al., 1995).   
1.6.4 Serine protease 
A fourth allergen was identified in the venom of paper wasps (Pantera et al., 2003 
Winningham et al., 2004, and Fitch et al., 2006).  Analysis of this protein showed it to be 
a trypsin-like serine protease.  A homologous allergen has not been identified in venom 
of yellow jackets and hornets; however, a serine protease has been isolated from venom 
of both honey bees and bumble bees (Jeep et al., 1996, Kettner et al., 1999, Wood and 
Hoffman, 1983, Winningham et al., 2004).  
Serine proteases are a well characterized family of molecules due to their 
importance in a variety of biological processes, such as blood coagulation, digestion, 
fertilization, extracellular and peptide degradation, and mast cell function.  These 
enzymes cleave the carbonyl side of arginine and lysine.  Typically, serine proteases  
circulate as zymogens, a portion (propeptide) of the enzyme that resembles the 
tetrahedral intermediate occupying the active site.  Cleave of the propeptide activates the 
enzyme and is irreversible.    
 21 
Serine proteases have common structural features important for catalytic activity.  
The catalytic triad, a functional group of histidine, serine and aspartic acid residues, is 
essential for the cleavage of the substrate.  These residues are found closely together 
while the protease is in proper conformation, however, sequentially they are spaced apart 
in the amino acid sequence.  The cleavage of peptides occurs in the tetrahedral state by 
forming hydrogen bonds with the negatively charged groups of the substrate, which is 
stabilized by the histidine residue.  These groups form an oxyanion hole, which is 
important for stabilization In addition to the oxyanion hole, the formation of hydrogen 
bonds between the loop region of the enzyme and the substrate aid in stabilizing the 
reaction (Branden, 1999).    All proteases have a general cleavage site; however, partial 
specificity can be inferred by conformation.  Specificity is greatly influenced by the 
binding pocket, which dictates the residues that precede the site of cleavage (Devlin, 
1997).   
The introduction of the substrate into the binding pocket of the serine protease 
initiates a complex mechanism which results in the cleavage of the substrate.  During 
stabilization of the substrate in binding pocket the histidine accepts a proton from the 
serine, allowing nucleophilic attack by the serine on the carbonyl carbon of the peptide 
bond on the substrate.  Next, the histidine donates a proton to the peptide creating a 
protonated amine on the tetrahedral intermediate, allowing for the release of an amine 
product.  Afterwards, nucleophilic attack by water breaks down the tetrahedral 
intermediate causing the release of the carboxyl product (Devlin, 1997, Branden, 1999, 
and Hostrom, 2002).   
 22 
Serine proteases from paper wasps and honey bees have been characterized and 
compared.  The serine protease allergen from honey bees (Api m 7) has been cloned and 
characterized.  This protease is 245 amino acids in size, with a leader sequence of 35 
amino acids, followed by an 88 residue CUB domain (complement, an embryonic sea 
urchin protein, a bone morphogenetic protein interaction domain), a 31 residue linker, 
and  a 13 amino acid propeptide region.  The catalytic triad is present and the entrance to 
the binding pocket is a methionine, suggesting this molecule may not be a functional 
enzyme due to the size of the residue.  This is supported by the inability of Api m 7 to 
bind to benzamidine.  The mature molecule has four potential N-glycosylation sites, but 
only one of these appears to be glycosylated (Winningham et al., 2004).  
The serine protease isolated from the European paper wasp P. dominulus (Pol d 4) 
has been cloned and characterized.  This sequence contained a 19 amino acid leader 
sequence, a 14 amino acid propeptide, and a mature molecule that was 244 amino acids 
in size. Analysis of the P. dominulus serine protease sequence (Pol d 4) showed it is a 
trypsin-like molecule with six potential N-glycosylation sites (Fitch et al., 2000 and 
Winningham et al., 2004).  Initial observation during isolation of Pol d 4 suggest that two 
to four of these sites may be glycosylated.  When compared for identity, Pol d 4 and Api 
m 7 are 41.5% identical; Pol d 4 and the bumble bee serine protease are 31.8% identical; 
and the honey bee and bumble bee proteases are 33.1% identical (Winningham et al., 
2004).   
The serine protease from another species of the European paper wasps, P. gallicus 
(Pol g 4) has been isolated and studied.  This molecule is approximately 33.5 kDa in size 
and the first sixteen amino acids of the N-terminus were sequenced (Pantera et al., 2003).   
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The similarity between Pol d 4 and the N-terminal sequence of Pol g 4 (1-16) shows 
92.3% sequence homology (Pantera et al., 2003 and Winningham et al., 2004).  The 
ability of Pol g 4 to specifically bind IgE was assayed using the enzyme allergosorbent 
test (EAST) and showed that it may be a significant allergen in the venom of P. gallicus.  
RAST performed with Pol g 4 and Pol d 4 demonstrated that these allergens have the 
ability to bind approximately the same amount of IgE (Pantera et al., 2003).  Direct 
RAST with European patient sera showed more IgE bound the serine proteases from both 
species than to the Antigen 5 allergen.   
The serine protease allergen has been isolated from venom of North American 
paper wasps P. exclamans (Pol e 4).  Sera from American patients (sensitized to New 
World paper wasps) and European patients (sensitized to European and North African 
paper wasps) were used to assay the cross reactivity between Pol d 4 and Pol e 4.  IgE 
from both groups of patient sera bound to serine protease allergens.  RAST showed 
American patient sera bound more to Antigen 5 than to the serine protease.  The IgE from 
European patients bound both serine proteases during inhibition assays (Winningham et 
al., 2004).  The pattern of IgE binding to the allergenic serine proteases suggests that 
there are shared epitopes. However, inhibition studies suggest species-specific epitopes 
may have been generated in individuals sensitized by Old World paper wasps.  Both 
proteases have demonstrated the ability to bind benzamidine, suggesting the catalytic 
portion of both molecules is conserved (Hoffman et al., 1998 and Winningham, et al., 
2003).  Differences in amino acid sequence are most likely to occur in the loop 
framework of the serine protease.  
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1.7  Treatment of allergic reactions 
 Treatment for an allergic reaction to insect venom is prescribed by a physician 
based upon the severity of the patient’s physical manifestations.  Those individuals who 
have a normal reaction to the sting are treated with analgesics and cold compresses.  
Pharmacological treatment of a more severe reaction, resulting in a large local reaction, is 
used to control swelling and manage pain.  Symptoms are managed with antihistamines 
and analgesics. Steroids may be used if the reaction is extremely wide-spread or disabling 
(Reisman, 2002).   
 Patients who experience anaphylaxis in response to an insect sting have short-and 
long-term treatment options.  Immediate treatments can be performed with epinephrine 
and antihistamines.  Antihistamines are taken to combat the effects of histamine 
delivered into the system.  Patients with a severe allergic response have the option of 
venom immunotherapy.  Immunotherapy is an effective means of treatment for patients 
with a severe reaction to venom allergens (Valentine, 1984 and Reisman and Livingston, 
1992).  This method involves the introduction of increasing amounts of allergen to 
patients over time to induce tolerance (Reisman, 2002).  Treatment of insect allergies 
with immunotherapy is approximately 90% effective.  The allergens used in this 
treatment are generally obtained as venom extracts, and the mechanism behind this 
particular treatment is not well understood.   
 The treatment of insect venom allergies with immunotherapy can pose some 
difficulties.  The species of the sensitizing insect dictates the type of venom extract used 
in treatment.  Identification of the causative insect can be complicated, some insect 
species can be mistaken for another or the sensitizing insect was not seen.  The 
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sensitizing species can be determined by a variety of diagnostic assays.  However, these 
assays may not be cost effective, typically resulting in a mix of venom extracts from 
representatives of stinging insect genera being prescribed.  Recent studies show that 
treatment with venom from one species of one genus may not fully protect from the sting 
of a different species of the same genus.  This could put the patient at risk for an 
anaphylactic episode when encountering their sensitizing species.     
 In the United States, the standard practice for immunotherapy is to use venom 
extracts; however, other countries are beginning to use allergens from alternate sources.  
The use of recombinant technology to produce large amounts of a given allergen has 
begun to gain popularity.  Recombinant production of the allergen allows for clean 
samples and control over the exact amount of the identified allergen used in treatment.  In 
addition, allergens can be mass produced, rendering it more cost effective.  Recombinant 
technology also allows for manipulation of the allergen to reduce immunogenicity but 
still conferring protection, which could prove to be safer for the patient (Grammer, 2002).   
1.8  Experimental objectives 
 The partial cross-reactivity observed between European and American paper wasp 
venom allergens affect the protection from immunotherapy among patients.  There are 
four medically significant allergens in paper wasps venom and two of these have the 
potential to contain unique epitopes.  These allergens are the venom hyaluronidase and 
serine protease.  Studies have shown hyaluronidase is cross-reactive without having 
significant identity between venom allergens.  This type of cross-reactivity may be due to 
post-translational carbohydrate and not amino acid epitopes.  The lack of sequence 
identity between hyaluronidase may contribute unique amino acid epitopes.  The serine 
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protease from European paper wasps has been shown to be cross-reactive with the serine 
protease allergen from American paper wasp venom.  However, in the presence of 
antigen 5, the European paper wasp serine protease continues to bind IgE, while the 
American paper wasp serine protease IgE binding drops significantly.  Characterizing 
allergenic proteins and their ability to bind IgE will lead to the production of safer and 
more effective treatments.  The use of recombinant protein technology is being used to 
understand and improve patient treatment.  Improvements in patient testing, will lead to 
more effective immunotherapy using the correct whole venom extract.   
 We hypothesize that the allergenic serine protease isolated from the venom of P. 
dominulus contains amino acid epitopes which contribute to the species-specific t 
immunologic response in patients.  In order to address this question, the serine protease 
from P. dominulus was expressed in eukaryotic and prokaryotic expression systems.  
Probable epitopes were predicted and analyzed to produce mutants of Pol d 4.  All 
recombinant proteases were assayed for their ability to bind IgE from sera obtained from 
patients sensitized to either European or North American paper wasps.  Finally, the 
sequence of the allergenic serine protease from P. gallicus was characterized. 
1.8.1  Expression of recombinant Pol d 4 
The production and characterization of recombinant Pol d 4 is necessary to 
evaluate IgE binding to the European paper wasp serine protease allergen.  Isolation of 
the native protein is difficult due to contaminating proteins and requires a great deal of 
time and materials.  Using recombinant prokaryotic and eukaryotic expression systems a 
non-glycosylated and glycosylated form of Pol d 4 can be produced to study IgE binding.  
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The apparent cross-reactivity between Pol d 4 and Pol e 4 can be a result of two 
components.  The first component may be the similarity between amino acid sequences 
of both molecules.  The second component contributing to the cross-reactivity between 
these molecules are post-translational N-linked carbohydrates that are added to the 
proteins.  In an effort to determine the effect of these components on IgE binding, the 
recombinant serine protease was produced in both eukaryotic and prokaryotic expression 
systems.   
The investigation of Pol d 4 in IgE binding is complicated by the incomplete 
purification of native proteins.  Amounts of other allergens, as small as 0.1-1%, can 
generate significant IgE binding.  Several researchers have addressed this by producing 
recombinant forms of various allergens.  Typically, these recombinant proteins are 
produced in insect cell lines using baculovirus expression systems.  These systems 
produce the native conformation of the protein and add post-translational glycosylation.  
Sf9 and High Five™ cell lines were evaluated for expression of Pol d 4.   
The High Five™ insect cell line was chosen for expression due to two factors.  
The first factor is the ability of the High Five™ cells to add certain post-translational 
carbohydrates.  The CCD, an important epitope in insect allergens, is mostly composed of 
an α 1,3 fucose core (Hemmer et al., 2001 Hemmer, et al., 2004, and Bencurova et al., 
2004).  The Sf9 cells appear to lack fucosylase function; however, the High Five™ cells 
have retained this function (Straudacher, 1992). The Sf9 and High Five™ insect cells 
lines were evaluated for the type of carbohydrates that are added during glycosylation.    
Based on this information, the High Five™ cells were chosen for protein production.  
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 The second type of epitope that may be responsible for IgE binding to Pol d 4 
involves post-translational glycosylation.  As previously discussed, post-translational 
glycosylation can contribute to cross-reactivity between venom allergens.  Examination 
of the cross-reactivity between Pol e 4 and Pol d 4 suggests that CCD may be involved.  
Data shows binding of American and European IgE to both Pol e 4 and Pol d 4.  Some of 
the apparent cross-reactivity between the Old World and New World paper wasp 
allergenic serine proteases may be a result of the carbohydrate present on the molecules.   
 In order to facilitate understanding of the binding of venom-specific IgE to the 
carbohydrate on Pol d 4, a recombinant protein was produced in a prokaryotic expression 
system.    This type of system allows for the production of a recombinant protein which 
possesses a uniform lack of carbohydrate.  Epitopes integral to the allergic reaction are 
typically conformation dependent.  Considering this information, attempts were made to 
fold the recombinant protein into its proper conformation.  These proteins were tested for 
IgE binding by probing with sera obtained from individuals sensitized to Old World 
paper wasps.    
1.8.2 Mutational analysis of Pol d 4 
Amino acid epitopes may contribute to the species-specific immune response 
between Old World and New World paper wasp venoms.  This type of antigenic 
determinant would provide unique epitopes within the venom which may play a role in 
species-specific reactivity.  Determining the major amino acid epitopes on Pol d 4 will 
further aid in understanding its role in species-specific IgE binding.   
The major epitopes on Pol d 4 were identified and mutated to assay for IgE 
binding.  These epitopes can be distinguished by various computational programs.  
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Epitopes were evaluated as functional epitopes.  Specific amino acids in each epitope 
were mutated and expressed in the baculovirus system.  These amino acids were mutated 
to a neutral alanine.  After purification, proteins were assayed for IgE binding using 
European patient sera. 
1.8.3 Analysis of IgE binding to recombinant Pol d 4 
 The contribution of Pol d 4 to the unique pool of allergenic epitopes can be 
determined by studying the binding of patient IgE to the potential epitopes found on 
recombinant forms of Pol d 4.  The importance of post-translational glycosylation was 
evaluated by assaying IgE binding to recombinant Pol d 4 and inhibition studies with Pol 
d 4.  The three mutant forms of Pol d 4 were used to assay potential major epitopes on the 
surface of Pol d 4.   
1.8.4 Analysis of sequence homology among venom serine protease allergens 
Data has shown that the allergenic venom serine proteases from P. gallicus and P. 
dominulus bind approximately the same amount of IgE (Sanchez et al., 1995 and Pantera 
et al., 2004).  Further, investigators have shown that Pol g 4 is a major allergen in P. 
gallicus venom.  This data is supported by the phylogenic relationship between insects 
and their allergen homology.  The similarity in binding could be due to post-translational 
carbohydrates or common amino acid epitopes.   In order to clarify the relatedness 
between Pol g 4 and Pol d 4, the nucleic acid sequence of the Pol g 4 allergen was 
isolated.  This sequence will allow for characterization of Pol g 4 and allow for the 
comparison to Pol d 4.  The data will show identity between the two molecules and cross-
reactivity between the venom serine protease from P. gallicus and P. dominulus.    
  
Chapter 2:  MATERIALS AND METHODS 
2.1 Expression systems  
2.1.1 Eukaryotic expression:  baculovirus expression system 
The baculovirus expression system has been used extensively for the production 
of recombinant proteins from various organisms.  This system has the advantage of being 
safe, easy to expand, and can express high levels of target protein.  In addition to these 
attributes, this system is optimal for expression of an insect-derived protein because 
processing of the protein will be similar to that of the native molecule.  Among the 
various baculovirus expression systems, the Bac-to-Bac® system, purchased from 
Invitrogen (Carlsbad, CA), was chosen for the expression of Pol d 4. 
The Bac-to-Bac™ system utilizes the ability to generate recombinant virus  by 
site-specific transposition (Ciccarone et al., 1997). A Tn7 transposition is used to insert 
the gene of interest into a bacmid DNA which is then propagated in E. coli (Luckow, 
1993).  Transposition events can be determined by blue/white colony selection, due to 
distribution of the lacZα gene during transposition.  Host cells are then transfected with 
bacmid DNA for viral and protein production.   
2.1.2   pFastBac™ 1 
The pFastBac™ 1 vector (Anderson et al., 1996) (Invitrogen) was used for sub-
cloning the gene of interest.  This vector contains the sequence for the AcMNPV 
polyhedron promoter followed by a large multiple cloning site.  The vector has a SV40 
polyadenylation signal and genes for ampicillin and gentamicin resistance.  The vector 
also contains Tn7 transposition sites which correspond to the target mini-attTn7 on the 
shuttle vector (bacmid) (Barry, 1988). 
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2.1.3  Insect cell lines 
2.1.3.1 Sf9 insect cells 
 Transfection of recombinant baculovirus was performed using the Sf9 insect cell 
line (Invitrogen).  These cells were derived from the Spodoptera frugiperda (fall army 
worm) pupal ovarian cell culture Sf21.  They are adapted for growth in serum-free media 
and can be grown as semi-adherent monolayer or suspension cultures.  Sf9 cells are 
optimized for transfections, plaque assays, viral production, and protein expression.    
2.1.3.2  High Five™ insect cells 
 The insect cell line High Five™ (Invitrogen) was used for expression of 
recombinant proteins.  This cell line was derived from ovarian cells isolated from the 
Trichoplusia ni (cabbage looper).  This cell line was adapted for suspension cultures and 
growth in serum-free conditions.  High Five™ cells have the capability to produce 5-10 
fold more recombinant protein than Sf9 cells.   
2.1.3.3 Insect cell care and storage 
 The Sf9 and High Five™ (Invitrogen) cell lines were maintained as suspension 
cultures.  All cultures were continuously incubated at 27°C, shaking at 225 RPM in a 
Lab-Line
®
 incubator-shaker (Labline, Melrose Park, IL). The Sf9 cells were cultured in 
Sf-900™ II SFM (Gibco, Carlsbad, CA) containing 50 mg/L of gentamicin (Gibco).  
Express Five
®
 SFM (Gibco) containing 50 mg/L of gentamicin and 2 mM L-glutamine 
(Gibco) was used to maintain the High Five™ cells. 
 Aliquots were stored in liquid nitrogen to re-establish cultures of Sf9 and High 
Five™ cells.  The cellular aliquots contained 1 X 107 cells in 1 ml of storage media [45% 
conditioned media, 45% fresh SFM media, and 10% DMSO].  Conditioned media was 
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created by culturing cells in fresh media.  Aliquots were frozen gradually at -20°C, then -
80°C, and finally stored in liquid nitrogen.  
2.1.4  Prokaryotic expression:  pET expression system 
The pET expression system (Novagen, San Diego, CA) is a large group of plasmids 
intended for use in the prokaryotic expression of target proteins (Studier and Moffatt, 
1986, Rosenberg et al., 1987, and Studier et al., 1990).  The gene of interest is cloned 
into an expression vector under the control of the bacteriophage T7 RNA polymerase.   
The vector is transformed into host cells with chromosomal T7 RNA polymerase under 
the control of lacUV5.  This control allows the expression of the gene of interest to be 
silent until induction with IPTG (Stuier et al., 1990 and Dubendorff and Studier, 1991).   
2.1.5  pET-17b vector 
We used the pET-17b (Novagen) expression vector for the production of 
recombinant Pol d 4.  This vector encodes for ampicillin resistance, N-terminal T7 tag, 
and a multiple cloning site (MCS) consisting of 15 restriction sites.  Target genes were 
ligated into the vector using Nde 1 and Bam HI restriction enzymes on the 5´ and 3´ends 
respectively.   
2.1.6  Prokaryotic cells 
2.1.6.1  Rosetta-gami™ 2 E. coli cells 
Rosetta-gami™ (DE3) competent E. coli cells (Novagen) were chosen for 
prokaryotic expression mainly for their ability to account for the codon bias between 
eukaryotes and prokaryotes.  These cells were developed from two host strains.  The first, 
Origami 2, are derived from K-12 E. coli cells and enhance the production of disulfide 
bridges (Bessette et al., 1999 and Prinz et al., 1997).  The second strand is the Rosetta 
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cell line which is derived from BL21 E. coli cells (Phillips et al., 1984).  The Rosetta 
contains tRNAs for seven of the rare codons in E. coli.  Rosetta-gami™ cells carry IPTG-
inducible T7 polymerase.  These cells are chloramphenicol-resistant and kanamycin-
sensitive. 
2.1.6.2 Preparation of chemically competent cells 
 Chemically competent E. coli cells were made every six months to ensure 
optimum transformation.  Single colonies from frozen stocks were used to inoculate 250 
ml of SOB media [20 g tryptone, 5 g yeast extract, 0.6 g NaCl, 0.5 g KCl, 10 mM MgCl2, 
and 10 mM MgSO4] then incubated on a shaker at 225 RPM at 18°C. Incubation 
continued until absorbance at OD600 was 0.6.  The culture was placed on ice for 10 min., 
transferred to centrifuge bottles, and centrifuged for 10 min. at 2500 x g at 4°C.  The 
supernatant was removed and the pellet was resuspended in 80 ml of ice-cold TB [10 mM 
HEPES, 55 mM MnCl2, 15 mM CaCl2, and 250 mM KCl].  After a 10 min. incubation on 
ice, the pellet was collected by centrifugation as previously described.  The pellet was 
resuspended in 20 ml of TB, and DMSO was added to a final concentration of 7%.  The 
cellular suspension was separated into 100 μl aliquots and frozen in liquid nitrogen.  
Stocks were maintained at -80°C. 
2.2 Primer design 
 All primers are listed in Table 3.  Primers were ordered from Invitrogen 
(Carlsbad, CA) and were desalted.  Distilled water was used to rehydrate all primers to a 
working concentration of 400 ng/ml. 
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Table 3: A list of primers used for sub-cloning, insert verification, and DNA 
mutation.  The nucleic acids are represented by one letter designations, adenine (A), 
Thymine (T), guanine (g) and Cysteine (C).  The letter V represents A, G or C and N 
represents A, C, G or T. 
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Primer Name Sequence          Purpose 
  
HINDLD3´ GAGAAGCTTTTATGATGATGATGATGATGATCCGCCTTGCAGTATGTTTCTCC   Cloning 3´end for in baculovirus expression of GrPol d 4 
BAMLD5´ GAGGGATCCATGAATTCTGGTAAAATTATTTTTATTATTTA    Cloning 5´end for in baculovirus expression of GrPol d 4 
BAM3´  GAGGGATCCTTAATGATGATGATGATGATGATCCGCCTTGCAGTATGTTTCTCC  Cloning 3´end for in E. coli expression of NrPol d 41 and  
NrPol d 42 
NDEPRO  GAGCATATGGAAGAAAATTGTAAATGTGGCTGGG     Cloning 5´end for in E. coli expression of NrPol d 41 
PDPETMAT GAGCATATGATAGTAAATGGTGTTGAAACAGAAA     Cloning 3´end for in E. coli expression of NrPol d 42 
PFASTFWD ATTCATACCGTCCCACCATC        Sequencing the pFastbac 1 expression vector 
PFASTREV CCTCTACAAATGTGGTATGGC       Sequencing the pFastbac 1 expression vector 
BVREV  AGCGGATAACAATTTCACACA       PCR verification of viral transposition 
BVFWD  CCCAGTCACGACGTTGTAAAA       PCR verification of viral transposition 
MUT 1           GCAATTGTTAAAACAAATGAAAGATTTGCATATTCGATGGCAGTTGGACCAGTTTTG   Mutant 1 forward primer 
MUT 1 ANT CGTTAACAATTTTGTTTACTTTCTAAACGTATAAGCTACCGTCAACCTGGTCAAACAG  Mutant 1 reverse primer 
MUT 2  GGTTGGGGTAAATTGCGTATAATGGTC      Mutant 2 forward primer 
MUT 2 ANT CCAACCCCATTTAATCGCATATTACCAG      Mutant 2 reverse primer 
MUT 3  CGAGAATAGTAAATGGTGTTGCAACAGAAATAAATGAATTTCCCATGGTGGCAC  Mutant 2 forward primer second set of primers 
MUT 3 ANT GCTCTTATCATTTACCACAACGTTGTCTTTATTTACTTAAAGGGTACCACCGTG  Mutant 2 reverse primer second set of primers  
MUT 4  GGGTCACCAGTTTTATGGCATTTATTGCTAACG CTACAATCGGAG    Mutant 3 forward primer 
MUT 4 ANT CCCAGTGGTCAAAATACCGTAAATAACGATTGCGATGTTAGCCTC    Mutant 3 forward primer 
CDS Primer TTTTTTTTTTTTTTTTTTTTTTTTTVN       cDNA generation primer 
FWDPRO  GAGGAAGAAAATTGTAAATGTGGC       Pol g 4 forward cloning primer 
3´GENOMIC GAGCCTCTTTGTATCAGTTCCGCCTAA      Pol G 4 reverse cloning primer 
 
 
                      
  
2.2.1 Design of primers for cloning 
 Primers were designed for sub-cloning and used in both the eukaryotic and 
prokaryotic expression systems in a similar manner.  All primers were designed to have a 
melting temperature (Tm) of approximately 65°C.  A GAG priming sequence was added 
to the 5´ end and the 3` primer included a hexa-histidine sequence prior to the stop codon.   
 Primers were engineered with restriction sites to facilitate ligation into the 
multiple cloning site (MCS) of the expression vector.  These included a Hind III 
restriction site on the 5` end primer prior to the DNA sequence and a Bam HI restriction 
site after the stop codon on the 3` end primer.  Primers designed for prokaryotic 
expression were designed for a Bam HI restriction sequence on the 5` end primer and a 
Nde I sequence on the 3` end primer.   
 The eukaryotic primers were designed to begin at the first methionine of the 
leader sequence isolated from Pol d 4.  A second set of eukaryotic expression primers 
contained the leader sequence for Sol i 2.  The primer for this construct was designed to 
include the Sol i 2 leader sequence and began at the propeptide sequence for Pol d 4 
(amino acid 19). 
 Primers for expression in the prokaryotic expression system were designed to 
begin amplification at different areas of the Pol d 4 gene.  The first 5´ primer began at the 
Pol d 4 leader sequence (amino acid 19) and the second 5´ primer began with the Pol d 4 
mature molecule (amino acid 40). 
2.2.2 Primer design for recombination virus verification 
 Primers were designed to verify the transposition of the gene of interest into the  
pFastBac™1 vector.  Sequences were chosen downstream and upstream of the mini-
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attTn7 transposition sites.  The forward primer was designed 130 bp upstream of the 
insertion site, while the reverse primer was 150 bp downstream of the insertion site.  Both 
primers were designed to have a Tm of approximately 68°C.   
2.3  Polymerase chain reaction 
2.3.1 Cloning reactions 
 Polymerase chain reaction (PCR) was used for amplification of the construct 
using Platinum
® 
Taq DNA polymerase (Invitrogen).   The following reaction mix was 
used:  1 µl template DNA (900 ng/µl), 5 µl 10X High Fidelity PCR buffer, 1 µl 10 mM 
dNTP (Invitrogen), 1.5 µl 50 mM MgCl2 (Invitrogen), 1.2 µl of each primer, 38.5 µl 
sterile water, and 0.5 µl Platinum
®
 Taq DNA Polymerase.  The reaction mix was 
overlayed with 50 µl mineral oil.  PCR amplifications were performed on a MiniCycler™ 
(MJ Research, Ramsey, MI).  Reactions were cycled 40 times using the following 
parameters: sample was denatured by heating to 94°C for 5 min., annealing was done at 
55°C for 45 sec., extension occurred at 68°C for 7 min., followed by a final 10 min. 
annealing step at 72°C after the last cycle.  An adenine overhang was added to PCR 
products for ligation into a TOPO
®
 TA Cloning
®
 vector (Invitrogen).  This was done by 
adding 0.5 µl Taq DNA polymerase (Invitrogen) to the PCR mix and incubating for 10 
min. at 72°C.   
2.3.2 Transposition and recombinant virus verification 
 The transposition of the proper vector:gene construct was verified by PCR.  The 
same procedure was used to verify the production of recombinant baculovirus.  A 50 µl 
reaction was set up using Taq DNA polymerase with final concentrations of the 
following reagents:  1X PCR buffer [200 mM Tris-HCl (pH 8.4), and 500 mM KCl], 0.1 
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mM dNTP, 1.5 mM MgCl2, 0.5 µM of each primer, 0.5 ng template, and 5 units Taq 
DNA polymerase.  Reactions were denatured for 3 min. at 93°C then cycled 40 times 
using the following parameters:  94°C for 45 sec., 55°C for 55 sec., and 72°C for 5 min.  
A final annealing of 72°C for 7 min. was performed.   
2.3.3 Agarose gel electrophoresis 
 PCR products were visualized by agarose gel electrophoresis using an 
Electrophoresis Systems Mini-Horizontal Unit (FB-SB-710, FisherBiotech (Pittsburgh, 
PA)).  Products were separated on a 0.8% agarose gel.  Gels were prepared by dissolving 
0.4 g Agarose (Invitrogen) in 50 ml 1X TBE [1 M Tris base, 0.5 M boric acid, and 2 mM 
EDTA], once dissolved, 5 µl 10 mM ethidium bromide (EtBr) was added.  The agarose 
was allowed to solidify at room temperature.  PCR products were prepared for 
electrophoresis by adding 5 µl agarose gel loading buffer [20% Ficoll 400, 0.1 M 
ethylenediaminetetraacetic acid (EDTA), 1% sodium dodecyl sulfate (SDS), and 0.25% 
Bromophenol blue].  A 100 bp ladder (Invitrogen) was prepared for electrophoresis by 
combining 1.5 µl ladder with 5 µl agarose loading buffer and 5 µl phosphate buffered 
saline (PBS).  Samples were loaded onto the gel and electrophoresed for 45 min. at 200V.  
Gels were visualized with the ChemiImager™ Ready System (Alpha Innotech 
Corporation, San Leandro, CA).   
2.4  Baculovirus expression 
2.4.1  DNA extraction 
 PCR products were extracted from agarose gels using the MinElute
®
 Fel 
Extraction Kit (Qiagen, Valencia, CA).  The band corresponding to the estimated size of 
the construct was excised using a sterile razor blade, weighed, and placed in a 1.5 ml 
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microcentrifuge tube.  QG buffer was added at three times the volume of the sectioned 
agarose sample and incubated at 50°C until the agarose was completely dissolved.  One 
volume of isopropanol was added and then the contents were mixed.  The DNA solution 
was transferred to a MinElute
®
 Spin Column and microcentrifuged for 30 sec. at 13,200 x 
g.  The flow-through was discarded, the column was cleaned by adding 750 µl of PE 
buffer, and centrifuged as before.  The flow-through was discarded.  The column was 
centrifuged again to remove residual ethanol.  The column was transferred to a fresh 1.5 
microcentrifuge tube, and 50 µl sterile water was applied to elute the DNA.  The sample 
was concentrated to 5 µl using a CentriVap Vacuum Concentrator (Labconco, Kansas 
City, MO).    
 The clone was ligated into the TOPO
®
 TA cloning vector (Invitrogen) for 
amplification and sequencing purposes.  The following were added to a 1.5 ml 
microcentrifuge tube: 3 µl concentrated PCR product, 1 µl undiluted salt solution [1.2 M 
NaCl and 0.06 M MgCl2], and 1 µl TOPO
®
 vector followed by incubation at room 
temperature for 15 min.   
2.4.2  Transformations 
 The ligation product was transformed into chemically competent XL-2 Blue E. 
coli cells (Stratagene).  Cells were stored in 100 µl aliquots at -80°C.  Three microliters 
of ligation product was added to cells and then incubated on ice for 30 min.   The reaction 
was heat shocked for 30 sec. at 42°C.  Transformations were incubated on ice for 2 min. 
followed by the addition of then 400 µl pre-warmed SOC (Invitrogen).  Cells were 
incubated at 37°C for 1 hr. while shaking at 225 RPM.   The transformation reaction was 
plated on LB + AMP plates [1.0% Tryptone, 0.5% Yeast extract, 1.0% NaCl, pH 7.0, and 
 40 
1 mg/ml Ampicillin] containing 20 mg/ml IPTG (Invitrogen) and 50 mg/ml BluoGal 
(Invitrogen).  Plates were incubated overnight at 37°C.  Positive colonies (white) were 
used to inoculate 10 ml of LB + AMP media, and then incubated overnight at 37°C while 
shaking at 225 RPM.   
2.4.3 Plasmid DNA isolation 
 Isolation of plasmid DNA was performed using the QIAprep Spin Miniprep kit 
from Qiagen following manufacturer’s instructions.  Cells were pelleted by centrifugation 
at 3,000 x g for 15 min.  The supernatant was discarded and the pellet was allowed to air 
dry for approximately 2 min.  The pellet was resuspended in 250 µl P1 buffer (with 
RNase A) and transferred to a 1.5 ml microcentrifuge tube.  Cells were lysed by adding 
250 µl P2 buffer and mixed gently.  The solution was neutralized by adding 350 µl N3 
buffer.  The isolation reaction was centrifuged at 14,000 x g for 15 min. at 4°C.  The 
supernatant was transferred to a QIAprep spin miniprep column containing 500 µl PB 
buffer.  DNA was collected on the membrane by centrifugation at 13,200 x g for 30 sec.  
The column was washed with 750 µl PE buffer.  A dry spin was performed, the column 
was transferred to a fresh 1.5 ml microcentrifuge tube, and DNA was eluted from the 
membrane with 50 µl sterile water.  Colonies were screened by restriction digest with 
EcoR I.  Each restriction digest had 10 µl isolated plasmid DNA, 2 µl REact
®
 3 buffer, 7 
µl sterile water, and 1 µl EcoR I (Invitrogen).  The reaction was incubated for 3 hrs. at 
37°C and then analyzed by agarose gel electrophoresis, as previously described.   
2.4.4  Nucleic acid sequencing  
 Verification of sequence integrity was done by nucleic acid sequencing. The  
Core Sequencing Facility at East Carolina University and University of Tennessee, 
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Knoxville were used to perform this service.  The M13 forward and M13 reverse 
sequencing primers (Invitrogen) were used.  Sequencing data was aligned and analyzed 
using the GCG (Genetics Computer Group) Software Package. 
2.4.5 Verification of gene ligation 
 Clones verified for sequence integrity, were removed from the TOPO
®
 vector and 
ligated into the pFastBac™ donor plasmid (Invitrogen, Carlsbad, CA).  The PCR product 
in the TOPO
®
 TA vector was extracted by restriction digestion with Bam HI and Hind III 
(Invitrogen).  The same digest was performed on the pFastBac™ vector in preparation for 
ligation.  In a 1.5 ml microcentrifuge tube, 10 µl isolated plasmid DNA or vector was 
added to 2 µl REact
®
 2 buffer, 6 µl sterile water, 1 µl Bam HI and 1 µl Hind III.  The 
reactions were incubated at 37°C for 24 hrs.   The pFastBac™ plasmid was phosphatase 
treated by adding 1 µl thermosensitive alkaline phosphatase (Gibco), incubated at 37°C 
for one hr., then a final incubation for 10 min. at 70°C.  The restriction digestion of the 
clone and pFastBac™ were electrophoresed on a 0.6% agarose gel and the correct bands 
were eluted using the MinElute kit as previously described.  Once eluted, the pFastBac™ 
vector and insert were concentrated to 30 µl and 5 µl, respectively.   
 Ligation of the insert into the pFastBac™ vector was mediated by T4 DNA 
Ligase (Invitrogen).  The ligation reaction consisted of 3 µl concentrated insert, 1 µl 
concentrated pFastBac™ vector, 1 µl T4 DNA ligase buffer, and 2 µl T4 DNA ligase.  
The reaction was incubated for 24 hrs. at 15°C.  The XL-2 Blue E. coli cells were 
transformed with the ligation reaction, plated, and plasmids were screened by digestion 
with Bam HI and Hind III, as previously described.  Clones were sequenced with the 
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PFASTFWD and PFASTREV primers (Table 3).   Sequences were evaluated with the 
GCG software package. 
2.4.6 Transformation of DH10Bac™ E. coli cells 
 The pFastBac™ system required the transformation of DH10Bac™ chemically 
competent E. coli cells using the donor plasmid (containing the gene of interest) to 
produce a recombinant bacmid.  After transformation into the XL-2 Blue E. coli cells, the 
pFastBac™ with the gene of interest was isolated with the QIAprep Spin Minprep kit.  
This plasmid was then used to transform DH10Bac™ cells, as previously described using 
1 µl isolated plasmid DNA.  Transformations were plated on DH10Bac™ LB plates 
containing 50 µl IPTG (20 mg/ml) and 50 µl Bluo-Gal (50 mg/ml).  Plates were 
incubated at 37°C for 48 hrs.  Positive colonies were streaked to isolate single colonies.  
DH10Bac™ media was inoculated with isolated colonies and grown overnight at 37°C 
shaking at 225 RPM.  Cellular stocks were frozen at -80°C with 25% glycerol.   
 The correct transposition event was analyzed using PCR.  Bacmid specific 
primers, BVREV and BVFWD (Table 3), were used with Taq polymerase under the 
following cycling conditions:  DNA was denatured at 94°C for 1 min.; annealing of 
primers for 45 sec. at 55°C, elongation of DNA for 2 min. at 68°C, the reaction was 
cycled 30 times, followed by a final elongation step at 72°C for 10 min.  PCR products 
were visualized using agarose gel electrophoresis (0.6% gel) as previously described. 
2.4.7 Bacmid isolation 
The transposition of the gene of interest was verified by PCR, the bacmid was 
isolated for transfection.  A 2 ml culture of DH10Bac™ media was infected with 5 µl 
frozen cell stock containing the construct.  Cultures were incubated overnight at 37°C 
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shaking at 225 RPM.  Cells were pelleted by centrifugation for 15 min. at 3,000 x g and 
the supernatant was aspirated.  The pellet was spun as before and the remaining 
supernatant was removed.  The pellet was resuspended in 300 µl Solution I [50 mM Tris-
HCl, pH 8.0, 10 mM EDTA, and 100 µg/ml RNase A] and transferred to a fresh 1.5 ml 
microcentrifuge tube.  Cells were lysed by adding 300 µl Solution II [200 mM NaOH and 
1% SDS], mixed, then incubated at room temperature for 10 min. The reaction was 
neutralized by the addition of 300 µl Solution III [3.0 M potassium acetate, pH 5.5].  
Samples were centrifuged at 14,000 x g for 10 min. at 4°C after incubating on ice for 10 
min.  The supernatant was transferred to a new microcentrifuge tube and centrifuged once 
more to remove all insoluble material.  The supernatant was added to 800 µl isopropanol 
and precipitated at -20°C for 16 hrs.  The bacmid was collected by centrifugation at 
14,000 x g for 5 min.  The supernatant was discarded, the pellet was washed twice with 
70% ethanol and allowed to air dry for approximately 5 min.  The bacmid DNA was 
dissolved in 40 µl sterile water and stored at 4°C for use the next day. 
2.4.8 Recombinant bacmid transfection 
Viral production was facilitated by transfection of the recombinant bacmid into 
Sf9 insect cells.  One day prior to transfection, 3 ml of log phase Sf9 cells, a total cell 
count of 2 x 10
6
 cells, were plated in a 25 cm
2
 cell culture flask (Corning, Corning, NY) 
and incubated at 27°C until cells reached 75% confluence.  Five micrograms of isolated 
bacmid (in 5 µl) was added to 100 µl Sf-900™ II SFM media (Invitrogen) without 
antibiotics; and 6 µl of Cellfectin
®
 reagent (Invitrogen) was added to 100 µl Sf-900™ II 
SFM media without antibiotics.  Both solutions were combined and incubated at room 
temperature for 30 min.  During incubation, plated cells were washed once with 2 ml Sf-
 44 
900™ SFM without antibiotics, and covered with 2 ml Sf-900™ II SFM media. 
Following incubation the lipid:bacmid solution was added to 2 ml Sf-900™ II media 
without antibiotics.  The transfection mix was added dropwise to the cells and incubated 
for 5 hrs. at 27°C.  The lipid:bacmid mixture was aspirated and replaced with 2 ml Sf-
900™ SFM II media without antibiotics.  Transfections were incubated for 7 days at 
27°C, until cellular infection and death was detected.   
After incubation, virus was harvested for further use.  The media was removed 
from the cells and centrifuged at 800 x g for 5 min.  The supernatant containing the 
recombinant virus was collected and 2% fetal bovine serum (FBS) was added to protect 
against protease activity.  All stocks were wrapped with aluminum to protect from light 
degradation and stored at 4°C. 
2.4.9 Isolation of viral DNA 
 The production of recombinant baculovirus was confirmed by the isolation of 
viral DNA and amplification with specific primers.  All viral isolations were performed 
in duplicate.  Debris was removed from 750 µl viral stock by microcentrifugation at 800 
x g for 5 min.  The supernatant was collected, combined with 750 µl 20% PEG [20% 
Polyethylene glycol in 1 M NaCl], and incubated at room temperature for 30 min.  After 
incubation, the isolation was centrifuged at 13,200 x g for 10 min.  The supernatant was 
discarded and the pellet was air dried for approximately 10 min.  The pellet was 
resuspended in 100 µl sterile water and proteins were degraded by adding 5 µl Proteinase 
K (20 mg/ml), and incubating at 50°C for 1 hr.   Proteins and nucleic acids were 
separated by adding 105 µl PCI [phenol:choloroform:isoamyl alcohol; 24:24:1] 
extraction buffer  to the viral sample.  Isolations were centrifuged at 13,000 x g for 10 
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min.  The supernatant was transferred to a tube containing 10 µl 3 M sodium acetate, 5 µl 
of 2 mg/ml glycogen, and 300 µl 100% ethanol.  Viral DNA was precipitated overnight at 
-20°C.  The precipitated DNA was centrifuged at 14,000 x g for 15 min. at 4°C.  The 
pellet was washed with 500 µl 70% ethanol, allowed to air dry for approximately 5 min., 
and resuspended in 10 µl sterile water. 
Viral isolation products were amplified by PCR to verify the presence of the gene 
of interest.  The reaction mix contained the following:  1 l BVREV primer, 1 l 
BVFWD primer, 1 l 10 mM dNTP, 5 l 10X PCR buffer, 2 l 50 mM MgCl2, 34.5 l 
sterile water, and 0.5 l Taq polymerase.  The same cycling parameters as the bacmid 
verification were used for identification of the presence of recombinant baculovirus.   
2.4.10 Amplification of recombinant baculovirus 
 In order to obtain enough virus for protein expression, the virus was propagated 
by several rounds of infection.  P2 viral stock was made by infecting 3 ml of log phase 
Sf9 cells, 2 x 10
6
 cells/ml, with 250 µl of the initial P1 stock the initial recombinant 
transfection.  The culture was incubated for 7 days at 27°C.   The P2 viral stock was 
harvested as previously described.  P2 viral stock was used to generate high titer stocks 
with log phase Sf9 cells in suspension, these cultures were inoculated with 100 µl P2 
viral stock for every 100 ml of culture.  High titer stock was harvested on day seven and 
stored as previously described in recombinant bacmid transfection. 
2.4.11 Small scale expression 
 Optimum expression conditions were established with small scale expression 
cultures.  An initial 20 ml Sf9 suspension cultures were set up with a cell density of 2 x 
10
6 
cells/ml in Sf-900™ II SFM media.  These cultures were inoculated with 2 ml high 
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titer viral stock.  The expression cultures were incubated for 7 days, with 5 ml samples 
taken on days 4, 5, and 6; with the remaining culture being harvested on day 7.  Each 
sample was centrifuged at 800 x g for 5 min.  The supernatant and cell pellet were stored 
at -20°C until analyzed.   
2.4.12 Expression optimization 
 After production of Pol d 4 was verified, the expression culture parameters were 
optimized.  To establish the appropriate amount of inoculum for protein production, 
various amounts of virus (1, 2, and 3 ml) were added to 20 ml Sf9 cultures.  Cultures 
were harvested on day 4 and purified. Once the appropriate incubation time and viral 
concentration was determined two insect cell lines, Sf9 and High Five™, were inoculated 
with 3 ml of virus and harvested on day 4.  All purification products were analyzed by 
SDS-PAGE and Western blotting. 
2.4.13 Purification of recombinant proteins 
 Protein production in these initial cultures was assayed by purifying recombinant 
proteins from expression supernatants and cell pellets by metal affinity chromatography.  
Talon
®
 metal affinity resin (Clontech, Mountain View, CA) was used as the stationary 
phase. 
2.4.13.1 Small scale purification 
 The supernatant was dialyzed using SnakeSkin pleated dialysis tubing (Pierce, 
Rockford, IL) with a molecular weight cutoff of 7,000 Da.  The dialysis buffer [50 mM 
Tris-HCl and 0.5 M NaCl, pH 8.0] was changed 5 times over a 24 hr. period.  Cell pellets 
were thawed at room temperature and 1 ml of 0.7% SDS was added.  The pellet was 
resuspended by vortexing, centrifuged at 14,000 x g for 5 min., and the supernatant was 
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collected.  The Talon
®
 resin for supernatant and pellet purification was equilibrated with 
the appropriate buffer, either dialysis buffer or SDS buffer, respectively.  A bed volume 
of 50 l Talon® was equilibrated with 3 ml of buffer by centrifuged for 3 min. at 800 x g.  
Samples were combined with the resin and incubated at room temperature for 15 min. 
under agitation.  Samples were centrifuged at 800 x g for 3 min. and the supernatant was 
collected.  The resin was washed twice with 1 ml of the appropriate buffer, centrifuged as 
before, and the supernatant was collected.  Elution was performed by adding 60 l 0.1 M 
EDTA to the resin and centrifuging. 
2.4.13.2  Large scale purification 
 After expression conditions were optimized, large scale expression was performed 
using High Five™ insect cells.  Expression cultures of 500 ml were inoculated with 50 
ml high titer stock.  Cultures were incubated for 4 days at 27°C, shaking at 225 RPM.  
Cultures were harvested by centrifugation at 10,000 x g for 5 min. and the supernatant 
was collected and filtered with a 0.22 m polyethersulfone filter (Corning).  After 
filtration, the supernatant was exchanged against dialysis buffer using SnakeSkin pleated 
dialysis tubing for 24 hrs. with 5 changes of the buffer.  The dialysis product was 
concentrated to a volume of 30 ml with an Amicon 202 (Millipore, Bedford MA) 
concentrator using YM-10 Ultrafiltration Discs (Millipore).  Purification of the 
recombinant protease was performed using Talon
®
 metal affinity resin.   A bed volume of 
750 µl was equilibrated with 30 ml dialysis buffer by centrifugation at 800 x g for 5 min.  
After equilibration, the resin and concentrated supernatant were incubated together, 
agitating, at room temperature for 45 min.  The resin was collected by centrifugation at 
800 x g for 5 min.  The supernatant was removed and the resin was resuspended in 10 ml 
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of dialysis buffer before being applied to a polystyrene gravity-flow column (Pierce).  
Columns were washed twice with 10 mM imidazole [10 mM imidazole, 50 mM Tris-
HCl, and 0.5 M NaCl, pH 8.0].  Bound protein was eluted with 6 ml 250 mM imidazole 
[250 mM imidazole, 50 mM Tris-HCl, and 0.5 M NaCl, pH 8.0] in 1 ml fractions. 
2.4.13.3  High performance liquid chromatography of expression products 
 The expression products from baculovirus expression were further purified by 
Cation- Exchange HPLC.  Elution samples were concentrated to a total volume of 1 ml.  
The sample was centrifuged at 13,000 x g for 30 min. to remove debris.  The sample was 
loaded onto a Mono S column (Pharmacia).  Elution was performed with 0-80% of 1 M 
NaCl, with 0.05 M sodium acetate, pH 5.2, gradient at 1 ml/min over 65 min. using a 
Waters 600 Controller.  OD280 of sample was determined using a Waters Tunable 
Absorbance Detector and 1 ml fractions were collected every min.   
2.5  Verification of recombinant protein expression 
2.5.1  Western blotting 
2.5.1.1  SDS-PAGE protein separation 
 SDS-PAGE was used to determine size and purity of all products.  Samples were 
diluted 1:1 with SDS loading buffer [29 mM Tris, pH 6.8, 32.5 mM glycerol, 3 mM SDS, 
6 mM dithiothreitol, and 1.7 µM bromophenol blue] and heated at 95°C for 5 min.  A 
Gold Precast 4-20% Tris/Glycine gradient gel (Lonza, Rockland, ME) was loaded onto 
M1651 700 vertical electrophoresis system (Bio-Rad) with SDS-PAGE electrophoresis 
buffer [25 mM Tris-HCl, 0.2 M glycine, and 3.5 mM SDS].  BenchMark
®
 Pre-Stained 
Protein Ladder (Invitrogen) or PageRuler
™ 
(Fermentas, Glen Burnie, MD) was used for 
size comparisons.  Samples were loaded at a volume of 15 µl and electrophoresed for 45 
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min. at 175V.  Once protein separation was complete, the gel was removed from the 
cassette and washed three times with 25 ml of distilled water while agitating gently.  
Samples were visualized by staining the gel with 50 ml of Imperial
™
 Protein Stain 
(Pierce) overnight.   The stain was removed and the gel was destained by soaking in 
distilled water for two days, with frequent water changes. 
2.5.1.2  Protein transfer to PVDF 
 Western blotting was an initial assay for recombinant protein production in both 
expression systems.  Blots were probed with an Anti-His (C Term) Antibody specific 
antibody (Invitrogen).  The samples were separated on SDS-PAGE as previously 
described.   Protein transfer to PVDF membrane was performed using a Multiphor II 
Electrophoresis System (Pharmacia Biotechnology, LKB Bromma).  The PVDF 
membrane was soaked in methanol, followed by a 5 min. incubation in water and then 
placed in transfer buffer [39 mM glycine, 48 mM Tris-HCl, 0.0375% SDS, and 20% 
methanol].  Whatman filters (18) were soaked in transfer buffer until fully saturated.  
Nine of the filters were carefully placed onto the anode.  The PVDF membrane was 
placed on top of the filters followed by the gel and finally the last nine filters.  The 
cathode was placed onto the stack and the gel was transferred at 40V for 50 min.  
 Once transfer was completed the membrane was blocked overnight with 5% BSA 
in TBS [25 mM Tris-HCl and 0.5 M NaCl, pH 8.0].  The membrane was washed twice 
with 15 ml of TBS for 10 min. while agitating gently.  The PVDF membrane was 
incubated for four hours with the anti-6 his C terminal antibody diluted 1:5000 in 1% 
BSA in TBS, pH 8.0.  The membrane was washed twice with TBST [TBS and 0.02% 
Tween 20, pH 8.0] while agitating for 10 min.  The secondary antibody, anti-mouse IgG-
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alkaline phosphatase conjugate (Sigma), was diluted 1:5000 in 1% BSA in TBS.  The 
membrane was incubated with the secondary antibody for 2 hrs., then washed twice for 
10 min. with TBST.  The blot was developed with BCIP/NBT from Sigma.  The 
BCIP/NBT tablet was dissolved in 10 ml of sterile water and applied to the membrane for 
approximately 5 min. or until development was complete.     
2.5.2 MALDI-TOF mass spectrometry 
 MALDI-TOF mass spectrometry analysis was used to confirm production of 
recombinant proteins in both expression systems.  Molecular weights of intact proteins 
were determined.  The production of recombinant protein was verified by analyzing the 
tryptic digestion products and comparing tryptic peptide sizes against the predicted map. 
2.5.2.1  Preparation of intact protein 
 Whole protein and trypsin digestion products were analyzed to verify protein 
identity.  MALDI-TOF was performed on an Applied Biosystems Voyager-DE™ PRO 
Biospectrometry Workstation (Foster City, CA).  All data was collected using the 
manufacturer’s software, Voyager V5.1. 
      Intact protein samples were analyzed using the ProteoMass
®
 Protein MALDI-MS 
Calibration Kit (Sigma, St. Louis, MO).   Matrix was prepared by dissolving 10 mg 
matrix (3,5-Dimethoxy-4-hydroxycinnamic acid) in 1 ml 50%  Acetonitrile (ANC) and 
0.05% Trifluoroacetic acid (TFA) solution.  Elution samples were purified using C4 
ZipTips
®
 (Millipore), pipette tips containing chromatographic media for sample 
purification and concentration.  Samples were prepared in 2.5% TFA, for a final 
concentration of 0.1%-1.0%. ZipTips
®
 were wetted three times with 10 µl acetonitrile, 
then equilibrated three times with 0.1% TFA in distilled water.  The sample was loaded 
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onto the tip by aspirating and dispensing three to seven times.  The column was washed 
five times with 10 µl 0.1% TFA in water.  Protein was eluted with 75% acetonitrile and 
0.1% TFA in 4 µl, the solution was aspirated and dispensed three times, then collected.  
Samples were prepared for MALDI-TOF by mixing 10 µl of the matrix solution with 4 µl 
of filtered protein.  After mixing, 2 µl was spotted onto an Applied Biosystems sample 
plate and allowed to air dry at room temperature.  
2.5.2.2   Preparation of tryptic digest and guanidination of recombinant proteins 
 A more in-depth analysis of recombinant proteins was done using the In-Solution 
Tryptic Digestion and Guanidation Kit (Pierce), allowing for an accurate identification of  
proteins by detecting peptides present after cleavage with trypsin.   To a tube, 15 µl of 
digestion buffer [50 mM ammonium bicarbonate] and 1.5 µl of reducing buffer [100 mM 
tris (2-carboxyethyl) phosphine-HCl] were added to 10 µg sample protein, and the 
volume was adjusted to 27 µl with water.  This was incubated for 5 min. at 95°C.  After 
cooling, 3 µl of alkylating agent [100 mM iodoacetamide] was added and samples were 
incubated in the dark at room temperature for 20 min.  Samples were digested by adding 
1 µl of activated trypsin and incubated for 3 hrs at 37°C.  An additional 1 µl of activated 
trypsin was added and incubation continued overnight at 37°C. The digest was split to 
produce guanidinated and un-guanidinated fractions.  Guanidation was performed by 
adding 16 µl digestion products to 10 µl ammonium hydroxide and 6 µl 0.6 mg/µl O-
methylisourea hemisulfate, then incubated at 65°C for 12 min.  The reaction was stopped 
by adding 3 µl TFA.  Fractions were purified with C18 ZipTips
®
.  The conditions for 
whole protein preparation were used as previously described, with the exception of the 
elution buffer, peptides were eluted with 70% acetonitrile/0.1% TFA.   Preparation for 
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MALDI-TOF continued as previously described for whole protein assays except the 
matrix was alpha-cyano-4-hydroxycinnamic acid.  Generated fragment sizes were used in 
database searches for protein homology using the MASCOT program 
(www.matrixscience.com). 
2.6 Prokaryotic expression 
2.6.1 DNA isolation and ligation  
 The product from sub-cloning recombinant baculovirus expressed Pol d 4 was 
used as a template for expression in the E. coli system.  Two clones were generated for 
expression.  A common 3´ primer, BAM3´ (Table 3) incorporated a Bam HI restriction 
site and a hexa-histidine tag.  The 5´ primer for the first construct was designed to begin 
with the propeptide region and included a Nde I restriction site.   The 5´ primer for the 
second construct was designed at the beginning of the mature molecule and included a 
Nde I restriction site.  The clones were amplified by PCR under the same conditions 
described for baculovirus expression.  The PCR product was treated similarly to the  
baculovirus clone: ligated into the TOPO
®
 TA vector, sequenced, and verified with GCG.  
Confirmed clones were ligated into the pET-17b expression vector.  The ligation reaction 
was performed under the same conditions previously described for baculovirus 
expression.  Selected colonies were screened with restriction digestion using Nde I and 
Bam HI.   
2.6.2 Transformation into Rosetta Gami E. coli cells 
Transformations were performed as previously described in baculovirus 
expression, using 1 µl of ligation.  The transformations were plated onto LB + AMP +  
Chlor [1.0% Tryptone, 0.5% Yeast extract, 1.0% NaCl, pH 7.5, 34 µg/ml 
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chloramphenicol, 50 µg/ml ampicillin]and incubated overnight at 37°C.  Screening of 
single colonies was done by restriction digestion with Nde I and Bam HI.  
2.6.3  Expression in Rosetta-Gami
™
 E. coli Cells 
 Positive colonies were used to inoculate 10 ml of LB + Amp + Chlor and 
incubated overnight at 37°C, shaking at 225 RPM.  The cultures were diluted in 240 ml 
pre-warmed LB + Amp + Chlor media and incubated at 37°C while shaking at 225 RPM 
until OD600 was approximately 0.6.  IPTG was added to a final concentration of 0.4 mM 
and the culture continued to incubate for 3 hrs.    
2.6.4  Purification of recombinant proteins from prokaryotic expression 
 Purification of the Pol d 4 expressed in E. coli is based on a protocol described by 
King et al, (1996).  This procedure utilizes a denaturing condition, incubation at high 
temperature, and metal affinity chromatography to isolate and purify the recombinant 
proteins.  After incubation, cells were pelleted by centrifugation at 5,000 x g for 5 min.  
The pellet was washed with 10 ml wash buffer [0.05 M tris-HCl, 0.1 M NaCl, and 1 mM 
EDTA] and centrifuged at 5,000 x g for 5 min.  After washing, the pellet was 
resuspended in dissolve buffer [6 M guanidine, 0.1 M tris-HCl, and 5 mM 2-
mercaptoethanol] and incubated for 5 min. at 60°C. The clarified protein was collected by 
centrifugation at 11,000 x g for 20 min. at 4°C.  A 1 ml bed volume of TALON
®
 was 
equilibrated with dissolve buffer, 14 ml were added to the resin then centrifuged at 800 x 
g for 5 min.  Once equilibrated, the resin was added to the clarified protein and incubated 
for 45 min. at room temperature while agitating.  The resin was collected by application 
to a polystyrene gravity-flow column.  The resin was washed twice with 5 ml wash buffer 
[6 M urea, 50 mM tris-HCl, and 0.1 M NaCl, pH 8.0], and twice with 5 ml 5 mM 
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imidazole [5 mM imidazole, 6 M urea, 50 mM tris-HCl, and 0.1 M NaCl, pH 8.0].  
Bound protein was eluted with 6 ml 250 mM imidazole [250 mM imidazole, 6 M urea, 50 
mM tris-HCl, and  0.1 M NaCl, pH 8.0) in 1 ml fractions.  Identification of the 
recombinant protein was performed by SDS-PAGE, Western blotting, and MALDI-TOF. 
2.6.5 Protein refolding 
 The denaturing conditions used in purification produced unfolded recombinant 
protein.  Several methods of refolding were used and correct folding of the recombinant 
protease was verified using a Benzamidine column.    
 The first method of refolding used the dialysis of elution products from 
purification against PBS for 24 hrs. at 4°C with 5 buffer changes.  The second method of 
refolding involved exposure of elution products to decreasing concentrations of urea.  
The eluted recombinant protease, 3 ml, was dialyzed using SnakeSkin Pleated Dialysis 
Tubing.  Dialysis began in 6 M urea [6 M urea, 50 mM tris-HCl, and 0.1 M NaCl, pH 
8.0] for 4 hrs., then the concentration of urea was decreased to 4 M [4 M urea, 50 mM 
tris-HCl, and 0.1 M NaCl, pH 8.0] and the sample was dialyzed for an additional 4 hrs.  
The dialysis buffer was changed again to 2 M urea [2 M urea, 50 mM tris-HCl, and 0.1 M 
NaCl, pH 8.0] and the sample was dialyzed for 4 hrs.  The sample was then dialyzed 
overnight with dialysis buffer [50 mM tris-HCl and 0.1M NaCl, pH 8.0).  Lastly, the 
sample was dialyzed for 4 hrs. in sterile water.  The last method used the properties of 
redox reagents to facilitate the formation of disulfide bonds.  Three samples, 3 ml of 
purification elution each, were dialyzed in Redox Dialysis Buffer [10% glycerol, 5 mM 
EDTA, 10 mM reduced glutathione, and 1 mM oxidized glutathione] for 12, 18, and 24 
hrs at 4°C.   
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2.6.5.1  Benzamidine purification 
 Benzamidine is a competitive inhibitor of trypsin, and was initially used to isolate 
Pol d 4 from insect venom.  Since it binds to the folded active site, Benzamidine was 
used to verify proper folding of the E. coli expressed recombinant protein.  A gravity-
flow column was packed with 0.5 ml p-aminobenzamidine (Sigma).  The resin was 
washed with 6 ml Borate Buffer [0.17 M boric acid and 0.13 M NaCl].  The sample was 
loaded onto the column and allowed to flow through.  The column was washed with 3 ml 
Borate Buffer.  Elution of bound protein was performed with 2 ml of  benzamidine 
Elution Buffer [0.1 M benzamidine, 0.17 M boric acid, and 0.13 M NaCl], collected in 1 
ml fractions.  Elution fractions were dialyzed overnight against distilled water to remove 
benzamidine before samples could be used for analysis (Winningham et al., 2004).   
2.7 Mutational analysis 
2.7.1 Identification of major epitopes 
 Little information is known about the structure of insect serine proteases.  There is 
no known crystal structure for this family of molecules from insects.  Further, 
information about IgE binding to the allergenic serine protease is scarce.   Therefore, to 
better understand binding of IgE to the allergenic serine protease, major amino acid 
epitopes were computational predicted and mutated to assay IgE binding. 
 Epitopes selected for mutation were chosen from information compiled from three 
sources, increasing the probability of correctly predicting the major epitopes.  The Pol d 4 
sequence was up-loaded onto two prediction servers.  The Conformational Epitope 
Prediction (CEP) Server (http://bioinfo.ernet.in/cep.html) was used to predict the possible 
allergenic epitopes (Kulkarni-Kale, 2005).  The InterProSurf:Protein Protein Interaction 
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Server (IPI) (http://curie.utmb.edu) was used to determine residues that could be involved 
in protein-to-protein interaction (Negi et al., 2006).  The mature molecule sequence was 
used in SWISS-MODEL (http://swissmodel.expasy.org provided by Swiss Institute of 
Bioinformatics Biozentrum) to produce a working model of Pol d 4.  This model was 
based on known existing structures that had a 36-48% homology with Pol d 4.  The 
model was used with the SPDBV (http://spdbv.vitel-it.ch/) program to generate a charge 
distribution map.  Epitopes generated from CEPS were compared with residues predicted 
by the IPI server for commonality.  The shared residues were located for position on the 
residue charge map.  Epitopes are typically areas that are protrudent and have an isolated 
charge.  Epitopes which had residues that were generated by CEPS and the IPI server, 
and met the epitope criteria were chosen for mutation.  In total of six residues were 
chosen for mutation among four epitopes.  A neutral alanine residue was substituted into 
the chosen sites.   
2.7.2 Mutation of Pol d 4 
 The mutation of Pol d 4 was carried out using the QuikChange
®
 Lightning Site-
Directed Mutagenesis Kit (Stratagene).  All mutations were performed on the construct 
produced for baculovirus expression.   
2.7.2.1 Primer design for DNA mutation 
 To ensure the correct length of the primers and the proper annealing temperature, 
mutation primers were designed using the QuikChange
®
 Primer Design Program 
provided by Stratagene (Los Angeles, CA) on-line.  Mutation primers (Table 3) were 5´ 
phosphorylated and cartridge purified (Invitrogen).   
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2.7.2.2 Mutation 
   Mutation reactions were performed using the QuikChange
®
 Lightning Site 
Directed Mutagenesis Kit from Stratagene.  This system utilizes PCR to introduce 
mutations into a target sequence with the use of specific primers.  All mutation reactions 
were performed using thin-walled PCR tubes (Bio-Rad, Hercules, CA) and was run with 
a MyCycler™ (Bio-Rad).  Reactions were set up as follows:  5 µl 10X QuikChange® 
Lightning Buffer, 50 ng DNA template, 100 ng appropriate primer (Table 3), 1 µl 10 mM 
dNTP, 1.5 µl QuikSolution
™
, 39.5 µl sterile water, and 1 µl QuikChange
®
 Lightning 
Enzyme.   The following conditions were cycled 18 times after a 2 min. denaturation at 
95°C:  20 sec. at 95°C, annealing for 10 sec. at 60°C and extension at 68°C for 3.5 min.  
A final extension was held for 5 min. at 68°C. 
 Methylated DNA was digested with 2 µl Dpn I restriction enzyme at 37ºC for 5 
min.  XL10-Gold
®
 Ultra-competent Cells (Stratagene) were transformed with the digest 
reaction.  Forty five microliters of XL10-Gold cells were thawed on ice and placed into a 
polypropylene round bottom tube, and then 2 µl β-mercaptoethanol was added.  Cells 
were incubated on ice for 2 min. and 2 µl of digested DNA was added.  The 
transformation reaction was incubated on ice for 30 min.  Cells were heat shocked at 
45°C for 30 sec., then rested on ice for 2 min.  The reaction was diluted with 400 µl of 
pre-warmed SOC and incubated at 37ºC for 1 hr., shaking at 225 RPM.  Transformation 
products were plated on LB + Amp plates and incubated at 37°C overnight.   
 Possible mutants isolated from formed colonies were sequenced and aligned to 
verify mutations and reading frame. Mutant 3 required two rounds of mutation PCR 
because of the distance between the residues being mutated.  The mutation of residue 135 
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was performed at an annealing temperature of 68°C.  Mutants were expressed in the 
baculovirus system and purified as previously described.   
2.8  Patient sera 
  Patient sera were acquired by Dr. P. Campi of Florence, Italy and Dr. M. Blanca 
of Malaga, Spain from individuals sensitized to European paper wasps.  All samples were 
collected with informed consent.  The use of previously collected deindentified sera from 
allergic patients in these studies has been determined to be exempt by the UMCIRB. 
2.9  Immunoblotting 
 The ability of patient IgE to bind to recombinant proteins was assayed by 
immunoblotting.  The purified products of baculovirus and E. coli expression, and a 
whole venom extract (Vespa Laboratories Inc., Spring Mills, PA) were used in each 
assay.  The whole venom extract serves as a control for IgE binding.  In preparation for 
blotting, the purified recombinant samples were concentrated 10 times and the whole 
venom extract was diluted 10 times. Samples were blotted by pipetting 1 µl onto 7 cm by 
0.7 cm Transblot Transfer medium pure nitrocellulose membrane (Bio-Rad).  A 
membrane was blotted for each patient sera assayed.   Blots were blocked using NAP 
Blocker (G Biosciences, St. Louis, MO) diluted 1:2 with TBS for 2 hrs. at room 
temperature.  After blocking, the membranes were washed three times with 20 ml of 
TBST [TBS + 0.005% Tween 20] for 5 min., agitating.  Each blot was incubated with a 
different patient serum, horse serum or negative human serum control.  The sera were 
diluted using 0.2 ml to 1 ml NAP Blocker (diluted 1:5 in TBS).  The blots were incubated 
with sera overnight with continuous rocking at room temperature.   The first wash after 
incubation was performed on each blot separately to avoid mixing of sera.  Two 
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additional washes were done with TBST for 10 min., agitating.  A human anti-IgE-
streptavidin conjugate (Vector Laboratories, Burlingame, CA) was diluted 1:1,000 in 
NAP Blocker (1:5 in TBS), added to blots, and incubated for 5 hrs. at room temperature, 
rocking.  The blots were washed three times as previously described.  Biotinylated 
alkaline phosphatase (Vector Laboratories) was diluted 1:3,000 with NAP Blocker (1:5 in 
TBS) and incubated with nitrocellulose strips for 1.5 hrs.  After washing three times, the 
blots were developed with BCIP/NBT (Sigma) as previously described.   
2.9.1  Immunoblotting inhibition 
 The ability of patient IgE to bind carbohydrate was assayed with immunoblot 
inhibition assays.  This assay was performed under the same conditions as 
immunoblotting.  However, prior to incubation with the nitrocellulose membrane the 
patient sera were incubated with 1 mg/ml of bromelain (Sigma).  Commercial bromelain 
is a combination of highly glycosylated cysteine proteases isolated from the fruit and 
stem of pineapple.  Both cysteine proteases contain multiple CCD epitopes and are 
commonly used in the inhibition of CCD specific IgE.   
2.9.2  Densitometry 
 The color intensity caused by the binding of IgE to the recombinant forms of Pol 
d 4 was measured by densitometry.  Immunoblot strips were visualized using a Bio-Rad 
ChemiDoc
™
 XRS and measurements and calculations were performed with the Bio-Rad 
Quantity 1-D Analysis One Software 4.6.5.  Measurements were done by selecting 
individual protein spots with the volume circle tool.  The density was calculated with the 
volume calculation tool.  Reports were exported to Microsoft
®
 Excel. 
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2.9.3  Calculations 
 All calculations were performed using Microsoft
®
 Excel.  The density of the 
soluble inhibition immunospot were subtracted from the density of the recombinant Pol d 
4 immunoblot protein spot on a immunoblot strip probed with the same sera.  The 
resulting number was divided by the density of rPol d 4 and multiplied by 100. The 
standard deviation of replicates was calculated as a percentage of the values. 
 Significant differences in IgE binding between the various proteins used were 
calculated with one-way ANOVA using PAWS.  Data obtained from the densitometric 
analysis of each immunoblot was used for analysis.  Replicates were averaged before use 
in the statistical test.  Data was analyzed in PAWS (predictive analysis software) (SPSS, 
Chicago, IL) using one-way ANOVA using a P=0.05.  A Bonferroni corrections test was 
also performed to address the multiple comparisons. 
2.9.4  Visualizing protein concentration on the immunoblots 
 In order to verify that the same amount of protein was used between each spot on 
the immunoblots proteins were blotted and then stained with protein stain.  Protein was 
spotted onto a strip of nitrocellulose membrane as previously described in the 
immunoblotting protocol.  The strip was immersed in Imperial
™
 Protein Stain (Pierce) for 
10 min.  The strip was rinsed with water overnight and allowed to dry at room 
temperature. 
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2.10  Characterization of the serine protease from P. gallicus 
2.10.1   Specimens 
 P. gallicus samples were provided by Dr. Stephano Turillazzi from the University 
of Florence, Italy.  Species were captured and placed in 100% Ethanol for shipment.  All 
specimens were stored at -80°C. 
2.10.2  RNA isolation 
 RNA was isolated using the NucleoSpin
®
 RNA II Total RNA Isolation kit from 
Macherey-Nagel (Bethlehem, PA).  In preparation for isolation, P. gallicus insects were 
centrifuged at 14,000 x g for 30 min. at 4°C.  The supernatant was discarded and insects 
were washed with PBS for 5 min. and flash frozen in liquid nitrogen.  The anterior 
portion of the gaster was excised with a sterile razor and placed in 15 ml Falcon tube 
containing 350 µl lysis Buffer RA1 and 3.5 µl β-mercaptoethanol.  Samples were 
homogenized by adding half the volume of 0.5 mm of glass beads and vortexed in 10 sec. 
intervals for 2 min.  The lysate was placed into a NucleoSpin
®
 Filter Columns and 
centrifuged for 1 min. at 11,000 x g.  The flow-through was prepared for column binding 
by adding 70% ethanol and mixed.  The lysate was loaded onto a NucleoSpin
®
 RNA II 
Column and centrifuged at 11,000 x g for 30 min.  The membrane was desalted by adding 
350 µl of Membrane Desalting Buffer (MDB) and centrifuging at 11,000 x g for 1 min.  
The DNase digestion mixture was prepared by combining 10 µl  DNase I (Invitrogen) 
with 90 µl DNase Reaction Buffer.  Ninety five microliters of the DNase reaction mixture 
was applied directly to the membrane and incubated at room temperature for 15 min.  
After incubation, 200 µl Wash Buffer RA2 was added to the column.  The column was 
centrifuged at 11,000 x g for 30 sec.    The column was washed by adding 600 µl RA3 
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Wash Buffer Concentrate and centrifuging at 11,000 x g for 30 sec.  A second wash with 
250 µl RA3 Wash Buffer Concentrate was centrifuged at 11,000 x g for 2 min.  RNA was 
eluted by adding 50 µl of sterile water to the membrane and spinning at 11,000 x g for 30 
sec., twice.  Samples were concentrated to 25 µl as previously described. 
2.10.3   cDNA synthesis 
 Total RNA isolated from P. gallicus was used to make cDNA with the SMART™ 
RACE cDNA Amplification Kit from Clontech.  In a microcentrifuge tube, 1 µg total 
RNA was mixed with 1 µl 5’ CDS primer, 1 µl SMART™ Oligo, and 2 µl water.  The 
reaction was incubated at 70ºC for 4 min., cooled on ice for 2 min., and microcentrifuged 
at 14,000 x g for 2 min.  The following reagents were added to the tube:  2 µl 5X 1
st
 
Strand Synthesis Buffer, 20 mM 1 µl DTT, 1 µl 10 mM dNTP mix, 1 µl anti-RNase 
(Ambion, Austin, TX), and 1 µl PowerScript
™
 Reverse Transcriptase (BD Bioscience).  
The solution was mixed, collected by centrifugation, and incubated for 1.5 hrs, at 42°C.   
 The cDNA reaction was purified using the MinElute
®
 PCR Purification Kit from 
Qiagen.  Five times the sample volume of Buffer PB was added to the mixture and then 
was transferred to a MinElute
®
 column.  cDNA was collected on the membrane by 
microcentrifugation at 14,000 x g for 30 sec.  The column was washed with 750 µl Buffer 
PE.  Remnants of ethanol were removed by microcentrifuging as before.  DNA was 
eluted from the column with 50 µl water.  The cDNA was concentrated to 25 µl as 
previously described. 
2.10.4   Cloning and sequencing 
 The cDNA generated from total RNA isolated from P. gallicus was used to 
amplify the gene for the allergenic serine protease.  Primers were designed from the 
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sequence of Pol d 4.  The 5’ end primer begins at the propeptide sequence and the 3’ 
primer ended with the stop codon.  Reactions were performed using Platinum® Taq DNA 
Polymerase (Invitrogen) and were set up as previously described.  
 Cycling conditions were altered to accommodate variability between the template 
and primers.  After an initial incubation at 94ºC for 5 min. the following temperatures 
were cycled 40 times:  94°C for 1 min., 48°C for 5 sec., 58°C for 5 sec., 68°C for 45 sec., 
and 2 min. at 72°C.  A final step at 72°C for 10 min. was performed.   
 The PCR products were evaluated by agarose gel electrophoresis.  Bands 
corresponding to the calculated size of Pol g 4 were excised and ligated into the TOPO
®
 
TA Vector (Invitrogen) as previously described.  Clones were screened by restriction 
digestion with EcoR 1 for an insert corresponding to the estimated size of Pol g 4.  
Plasmids were isolated, as previously described, from the appropriate clones were DNA 
sequenced.   
2.10.5  Analysis of DNA sequences 
 Sequencing data was up-loaded to GCG (Genetics Computer Group) Software 
Package.  Forward and reverse sequences were compared to verify the integrity of the 
sequence.  The sequence was aligned with the previously cloned Pol d 4 sequence for 
identity and homology.  A BLAST (Basic local search and alignment tool) search was 
performed via the NCBI (National Center for Biotechnology Information) internet server 
(http://www.ncbi.nlm.nih.gov/).  Nucleotide blasts were performed with the “nucleotide 
blast” option and amino acid blasts were performed using “protein blast”.  The nucleotide 
collection (nr/nt) database was used for nucleotide blast searches and non-redundant 
protein sequence (nr) database was used for protein blast searches. 
  
Chapter 3:  RESULTS 
3.1  Production of recombinant Pol d 4 
 Recombinant Pol d 4 was produced in several systems in order to investigate the 
epitopes involved in IgE binding.  Obtaining natural protein from venom is costly and 
labor intensive.   Eukaryotic expression of Pol d 4 allowed for the production and 
purification of recombinant protein.  Data has shown that certain asparagine-linked 
carbohydrates have the ability to bind IgE.  Protein production in insect cells creates an 
opportunity to have similar post-translational modifications to those found on native Pol 
d 4.  Since the presence of carbohydrate may play an important role in the binding of IgE, 
Pol d 4 was also expressed in a prokaryotic expression system, which lacks carbohydrate 
moieties.   
3.1.1 Eukaryotic expression of Pol d 4 
 The previously characterized Pol d 4 cDNA sequence was used for expression.   
The molecular structure was shown in Figure 3.  The first 19 amino acids make up the 
leader sequence.  This sequence is essential for cellular trafficking and final destination 
of the protein.  Amino acids 20-34 are the propeptide region of the protease.  This portion 
of the molecule maintains the serine protease in an inactive state (Devlin, 1997).  The 
remaining amino acids (35-244) determine the structure of the serine protease and include 
essential regions for protease activity.  The entire native sequence of Pol d 4 was cloned 
and expressed in the baculovirus expression system.  The production of recombinant Pol 
d 4 was optimized and assayed for yield and purity.  
Pol d 4 was cloned into the pFastBac
™
 expression vector with a hexa-histidine tag 
incorporated onto the N-terminus to facilitate purification.  Nucleic acid sequencing was 
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Figure 3:  Pol d 4 structure and function.  Pol d 4 sequence is divided into three 
distinct regions based on function.  The leader, propeptide, and mature molecule are 
shown.   The leader sequence facilitates protein trafficking.  The propeptide maintains the 
serine protease as an inactive zymogen.  The mature molecule contains essential regions 
for serine protease activity.   
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used to verify sequence integrity and incorporation of the sequence into the correct 
reading frame. Plasmid DNA, from positive clones, was isolated and transformed into 
DH10Bac
™
 E. coli cells containing a shuttle bacmid (DH10Bac
™
).  Correct transposition 
of the gene of interest was verified by PCR with specific primers. Isolated bacmids were 
transfected into Sf9 insect cells, then incubated for ten days.  After incubation the virus 
was harvested and used to make a large scale viral stock (P2).   
 High titer viral stock was used to express a small amount of recombinant protein 
to facilitate protein identification.  Cultures were incubated for 4 days, 5 ml samples 
taken every 24 hours.  Protein was purified from the supernatant and cellular extract of 
each sample by metal affinity chromatography.  These samples were analyzed by 
immunoblotting using a primary antibody specific for an N-terminal hexa-histidine tag 
(Figure 4).  A protein different from those found in uninfected cells was observed in 
supernatant 1 (A) and 2 (B) in increasing amounts from day 4 to day 6.  Antibody binding 
was observed in cellular extracts from clone 1 starting on day 5.   
 The viral clones that were positive for protein in the immunoblot were chosen for 
further investigation of the identity of expression products.  Clone 1 expression products 
was purified by metal affinity chromatography and prepared for visualization by SDS-
PAGE and Western blotting (Figure 5).  SDS-PAGE (A) showed a variety of proteins 
present in the purified protein.  A strong band was present at 42 kDa in both clones (lane 
1), larger than the calculated size of Pol d 4 (29 kDa).  Western blotting (B) showed a 42 
kDa protein in lane 1.   
 The nonspecific nature of the antibody used for Western blotting and the 
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Figure 4:  Dot blot of initial expression in baculovirus clones.  Expression of the 
baculovirus production of Pol d 4 was initially examined using a dot blot.  High titer viral 
stock was used to infect Sf9 cell cultures and incubated in suspension.  Samples of 
supernatants and cell pellets were collected on days 4, 5, and 6.  Protein from 
supernatants and cells were purified by metal affinity chromatography from two separate 
clones, 1 and 2.  Each sample was applied to the membrane in duplicate.  The dot blot 
was probed with an anti hexa-histidine antibody.  The purification products from clone 1 
(A), supernatant and pellet from incubation days 4, 5, and 6 were blotted in duplicate.  
Purification products from clone 1 showed the largest amount of expressed protein on 
day 6.  The purification products from clone 2 (B), supernatant and cell pellet, days 4, 5, 
and 6 of incubation were blotted in duplicate.  The expression products on day 6 showed 
the greatest amount of antibody binding in clone 2. The purification products from non-
infected cells (C), supernatant and cell pellet, were purified and blotted as control.  An 
additional control (D) of a previously verified recombinant protein expression was used 
as a binding control.   
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Figure 5:  SDS-PAGE and Western blot analysis of purified expression products of 
recombinant Pol d 4.    Expression products were purified using a Ca
2+
 metal affinity  
column and then assayed by SDS-PAGE and Western blotting.   The purification 
products were concentrated 5X and 15 µl used in SDS-PAGE (A).  A protein band was 
visualized at approximately 42 kDa.  The same amount of concentrated purified protein 
was used in Western blotting (B) which was probed with the anti-N-terminal hexa-
histidine tag antibody.  A protein band was identified seen at approximately 42 kDa.   
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unexpected larger size of the resulting product required further characterization of the 
recombinant protein.  Major proteins purified from the expression cultures were analyzed 
by MALDI-TOF mass spectrometry (Figure 6).  A large, broad peak was observed at 
35,195 Da.  Secondary peaks were seen at 14,068 and 24,756 Da.  The calculated size of 
Pol d 4 was 29 kDa, which was smaller than the 35,195 Da protein found MALDI-TOF 
mass spectrometry. 
 In order to identify the protein observed by MALDI-TOF mass spectrometry, 
protein finger printing was performed.  Purification products were reduced and alkylated, 
then digested with trypsin and 16 peptide fragments were identified by MALDI-TOF 
(Figure 7).  The peptide fragments that were observed from the trypsin digest of the 
whole purified protein were compared to the predicted fragments of Pol d 4 (Table 4).  
Nine of the peptide fragments matched the predicted tryptic peptide fragments of Pol d 4.  
A homology search using the MASCOT software search engine showed that the 
fragments had the greatest homology with Pol d 4 and covered 30% of the molecule 
(Figure 8).  Figure 8 shows the Pol d 4 derived amino acid sequence with regions covered 
by the protein finger printing highlighted in red.  Pol d 4 has six potential N-glycosylation 
sites which are underlined.  One of the six sites, N198, was included in a peptide 
fragments identified by MALDI-TOF.   If recombinant Pol d 4 is glycosylated, the 
presence of these sites during tryptic digest analysis would suggest that they are not 
glycosylated.  The remaining sites, N64, N84, N135, N138, and N246 may be candidates 
for post-translational glycosylation.   
   
  
 73 
 
 
 
 
 
 
 
 
 
 Figure 6:  MALDI-TOF mass spectrometry analysis of purified protein from 
baculovirus expression.  Pol d 4 expression products were purified by metal affinity 
chromatography.  Recombinant proteins were purified by metal affinity chromatography 
and a fraction of 0.1 to 10 µg was prepared for analysis by MALDI-TOF mass 
spectrometry.    A large broad protein peak was observed at 35,195 Da.   
 
 
 
 74 
  
9 9 9 9 .0 1 5 9 9 9 .4 2 1 9 9 9 .8 2 8 0 0 0 .2 3 4 0 0 0 .6 4 0 0 0 1 .0
M a s s  (m /z )
0
1 1 4 2 .0
0
1 0
2 0
3 0
4 0
5 0
6 0
7 0
8 0
9 0
1 0 0
%
 
I
n
t
e
n
s
i
t
y
Voyager Spec #1[BP = 35215.6, 1142]
3 5 1 9 5 .2 4
3 5 1 0 2 .2 3
3 4 9 6 7 .0 7
3 4 9 2 5 .8 8
3 4 8 0 9 .4 9
3 5 5 1 5 .3 8
3 5 5 7 0 .1 1
3 4 5 3 1 .3 6
3 5 6 6 4 .3 1
3 5 7 9 9 .5 9
3 4 4 1 3 .4 41 4 0 6 8 .6 5
3 5 9 5 8 .0 2
3 4 3 1 8 .9 2
3 5 9 2 1 .3 2
3 4 1 5 4 .3 0
3 5 9 8 7 .2 9
3 3 8 8 5 .5 3 3 6 0 8 9 .9 8
3 6 2 1 0 .3 2
3 3 7 3 8 .5 22 4 7 5 6 .9 6
3 6 2 8 9 .9 43 3 8 1 7 .1 3
3 3 6 3 9 .4 4 3 6 4 4 0 .4 4
1 6 1 9 0 .7 6
1 7 6 8 3 .3 51 1 1 0 9 .7 5 3 6 5 6 8 .7 93 3 1 2 1 .3 22 4 8 4 7 .4 0
1 4 0 1 8 .7 6 1 7 3 7 6 .7 91 0 5 9 1 .5 4 3 6 7 0 3 .8 43 3 3 5 1 .5 61 2 3 1 4 .6 6 2 4 9 2 9 .3 01 5 9 8 7 .7 6 1 7 7 2 1 .6 31 4 5 2 9 .3 4 3 6 9 9 8 .5 21 0 3 5 4 .7 1
1 1 8 8 9 .4 5 3 2 6 6 9 .1 32 5 0 9 4 .3 41 6 4 0 5 .9 61 3 6 9 9 .2 3 1 8 1 0 0 .6 4 3 7 2 2 7 .9 53 0 8 7 2 .2 1
1 1 0 4 9 .9 3 3 2 5 8 4 .0 92 4 5 2 5 .1 31 5 4 8 1 .2 81 3 9 4 2 .4 0 1 6 9 8 8 .7 7 2 2 9 3 1 .4 6 3 7 4 0 6 .5 82 6 3 2 2 .9 61 8 6 0 9 .8 5 3 0 7 4 5 .2 82 0 4 8 9 .8 81 4 6 4 4 .5 7 2 4 2 8 0 .0 51 6 5 5 8 .1 5 2 2 3 1 1 .1 2 3 2 3 9 8 .4 21 3 0 7 4 .5 5 3 7 8 2 7 .0 12 8 1 0 3 .8 7
2 5 9 2 7 .8 11 8 5 1 6 .0 8 2 9 7 9 7 .2 61 9 9 7 7 .2 6 2 3 9 3 6 .2 72 1 9 2 2 .4 9 3 8 4 6 9 .4 22 7 9 3 0 .6 2
 75 
 
 
 
 
 
 
 
 
 
Figure 7:  MALDI-TOF mass spectrometry analysis of tryptic fragments of 
baculovirus expressed Pol d 4.  Recombinant Pol d 4 was purified by metal affinity 
chromatography.  Trypsin was used to digest 10 µg of purified protein.  Fragments were 
prepared and analyzed with MALDI-TOF mass spectrometry.  Peaks at were identified at 
991.3, 1,080.6, 1,554.5, 1,589.4, and 1,918.5, corresponding with the predicted tryptic 
fragments of Pol d 4.   
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Table 4:  List of predicted tryptic peptide fragments of Pol d 4 and the matching  
fragments detected by MALDI-TOF mass spectrometry.  The derived sequence of Pol 
d 4 was up-loaded into the MS-Digest search engine to generate a list of predicted 
peptide fragments.  Five peptide fragments identified during MALDI-TOF mass 
spectrometry were identical to he predicted fragments, their molecular weights were, 
991.3, 1,080.6, 1,554.5, 1,589.4, and 1,918.5.  The fragments that corresponded with the 
predicted tryptic fragments are marked in  red.   
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       Fragment                Predicted Tryptic Fragments           MALDI-TOF Fragment (Th) 
1 
1
  EENCKCGWDNPSR  
13
 991.3 
2 
14
 IVNGVETEINEFPMVAR  
30
 1918.5 
3 
31
 LIYPSPGMYCGGTIITPQHIVTAAHCLQK 
60
  
4 
61
 YKR 
63
  
5 
64
 TNYTGIHVVVGEHDYTTDTETNVTK 
88
  
6 
89
 R 
89
  
7 
90
 YTIAEEVTIHPNYNSHNNDIAIVK 
114
  
8 
115
 TNERFEYSMK 
124
  
9 
125
 VGPVCLPFNYMTR 
137
 1554.5  
10 
138
 NLTNETVTALGWGK 
151
  
11 
152
 LR 
153
  
12 
154
 YNGQNKVLR
 162
  
13 
163
 K 
163
  
14 
164
 VDLHVITR
 171
 1080.6 
15 
172
 EZCETHYGAAIANANLLCTFDVGR 
195
  
16 
196
 DACQNDSGGPILWR 
209
 1589.4 
17 
210
 SPTTDNLILVGVVNFGR 
226
  
18 
227
 TCADDAPGGNAR 
23
8  
19 
239
 VTSFMEFIHNATGETYCK 
256
  
20 
257
 ADHHHHHH* 
265
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Figure 8:  Characterization of the derived Pol d 4 amino acid sequence with 
MALDI-TOF mass spectrometry data.  The amino acid sequence for the leader, 
propeptide, and mature molecule sequence are depicted.  Potential N-glycosylation sites 
are identified by an underscore.  Regions that were covered by protein finger printing                                                                                                                                              
peptide fragments are highlighted in red.                                            .                                         
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 1 EENCKCGWDN PSRIVNGVET EINEFPMVAR LIYPSPGMYC GGTIITPQHI VTAAHCLQKY 
 
61 KRTNYTGIHV VVGEHDYTTD TETNVTKRYT IAEVTIHPNY NSHNNDIAIV KTNERFEYSM 
 
121 KVGPVCLPFN YMTRNLTNET VTALGWGKLR YNGQNSKVLR KVDLHVITRE QCETHYGAAI 
 
181 ANANLLCTFD VGRDACQNDS GGPILWRSPT TDNLILVGVV NFGRTCADDA PGGNARVTSF 
 
241 MEFIHNATIG ETYCKADHHH HHH* 
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 The expression of Pol d 4 in the baculovirus system was confirmed by CTL BIO 
Services.  The intact protein was separated by SDS-PAGE, then digested with trypsin.   
Resulting peptide fragments were extracted, desalted and concentrated.   Fragments were 
analyzed on a Finnegan LTQ mass spectrometer using a one hour gradient and data 
dependent MS/MS collection (data not shown).  Multiple rounds of peptide sequencing 
showed the presence of two unique peptides, R.IVNGVETEINEFPMVAR.L and 
K.TNERFEYSMK.V, which were observed several times.  Analysis of these sequences 
showed that the recombinant protein scored extremely high for the venom serine protease 
from P. dominulus.   
 Expression was optimized for quantity and purity.  The optimal incubation time 
was 5 days post-inoculation.  Varying amounts of virus was added to cultures to 
determine ideal viral load.  Protein production data (not shown) determined that 8 ml of 
high titer stock per 100 ml of insect cultured yielded the highest amount (0.2mg/L) of 
recombinant protein.  The production of recombinant Pol d 4 in the Sf9 cells yielded a 
small amount of protein.  The production of protein was compared between the Sf9 and 
High Five™ insect cell lines.  Cells were infected with the same amount of virus, 
incubated the same amount of time, and purified using the same protocol.  Protein 
production was compared by visualization on SDS-PAGE (Figure 9).  The production of 
recombinant Pol d 4 was approximately the same in High Five™ cell but purity was low 
due to the presence of contaminating proteins.  Ultimately, the High Five™ cell line was 
ultimately chosen for expression based upon its ability to fully glycosylate recombinant 
proteins with fucoidan polysaccharides.   
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Figure 9:  Visual comparison of recombinant Pol d 4 produced by Sf9 and High 
Five™ insect cell lines.  High titer viral stocks were used to infect Sf9 and High Five™ 
insect cells.  Supernatants from both cell lines were harvested and purified by metal 
affinity chromatography.  Purification elutes were electrophoresed on a 4-20% SDS-
PAGE.  The recombinant protein was approximately 42 kDa in size.  Elution from 
protein produced in Sf9 cells are shown in lane 1 and those produced from High Five™ 
cells are in lane 2.  
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 After purification, several contaminating proteins and peptides were still visible 
on SDS-PAGE.  The purification products were separated by cation exchange HPLC 
(Figure 10).  The recombinant protease was isolated over a large sodium chloride 
gradient beginning at minute 30 until minute 45 (highlighted).  HPLC elution products 
were visualized by SDS-PAGE and Western blot (Figure 11).  The SDS-PAGE (A) and 
Western blotting (B) had a band at approximately 42 kDa, with secondary bands at 24 
and 19 kDa.   
3.1.2 Prokaryotic expression of Pol d 4 
 Expression in a prokaryotic system was performed to generate a recombinant 
serine protease which lacks post-translational glycosylation.  These proteins were used to 
assay the IgE binding to amino acid allergenic epitopes.  Two constructs were generated 
and expressed, one containing the propeptide and one without the propeptide.  Constructs 
were amplified by PCR, verified by nucleic acid sequencing, and ligated into the pET-
17b expression vector.  
Positive transformants were analyzed by restriction digestion with NDE I and 
Bam HI and visualized by agarose gel electrophoresis.  Isolated clones were transformed 
into Rosetta-gami™ (DE3) competent E. coli cells for expression.  Expression of non-
glycosylated protein containing the propeptide was initially analyzed by SDS-PAGE (A) 
and Western blotting (B) (Figure 12).  A band was visualized in both assays at 
approximately 31 kDa similar to the calculated molecular weight of the molecule which 
is 29.6 kDa.  The elution products were assayed with MALDI-TOF (Figure 13).  The 
protein size was 29.7 kDa (circled).  Trypsin digestion was performed for peptide 
sequencing.
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Figure 10:  Elution of recombinant Pol d 4 expressed in baculovirus from cation 
exchange HPLC.  Three liters of baculovirus expression cultures was harvested and 
recombinant protein was purified by metal affinity chromatography.  Purification 
products were separated by cation exchange HPLC.  The recombinant protease was 
confirmed in collections, by SDS-PAGE, Western blotting and MALDI-TOF mass 
spectrometry, over a large region of the gradient from minute 30 to minute 45 (boxed 
area). 
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Figure 11:  SDS-PAGE and Western blot analysis of elution products from cation-
exchange HPLC.  A. Fractions obtained from cation exchange HPLC were concentrated 
5X and 15 µl was used visualized protein by SDS-PAGE (A) and Western blotting (B).  
A. A protein band at 42 kDa was present.  B.  The Western blot was probed with an anti 
C-terminal histidine antibody.  A protein band was visualized at approximately 42 kDa. 
  
 
 
 
 
 
 
 
 
 88 
 
A. 
52 kDa
36 kDa
              
 
B. 
52 kDa
36 kDa
 
 
 
 89 
 
 
 
 
 
 
 
 
Figure 12:  Visual verification of E. coli expressed recombinant Pol d 4 by SDS-
PAGE and Western blot.  Expression of the non-glycosylated protease with the 
propeptide in E. coli cells was induced with IPTG.  Supernatant and cell pellets were 
harvested and protein was purified by metal affinity chromatography.  Fifteen microliters 
of the purification product was used in SDS-PAGE and Western blotting.  (A)  
Purification products were electrophoresed by SDS-PAGE.  A protein band was seen at 
approximately 31 kDa.  (B)  Western blot analysis was performed on purification elutes 
probing with an anti-C terminal hexa-histidine tag antibody.  A protein band was 
visualized at approximately 31 kDa.   
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Figure 13:  MALDI-TOF mass spectrometry analysis of intact recombinant Pol d 4 
with the propeptide expressed in the E. coli expression system.  Protein was purified 
from the expression of non-glycosylated Pol 4 with propeptide by metal affinity 
chromatography.  A fraction of 0.1 to 10 µg of purification product was analyzed by 
MALDI-TOF mass spectrometry and a strong peak (circled) at 29,698.86 Da.  The 
calculated size of Pol d 4 is 29.6 Da. 
 
 
 
 
 
 
 92 
 
1 9 1 1 1 .0 2 2 5 1 2 .4 2 5 9 1 3 .8 2 9 3 1 5 .2 3 2 7 1 6 .6 3 6 1 1 8 .0
M a s s  (m /z )
0
1 1 0 .7
0
1 0
2 0
3 0
4 0
5 0
6 0
7 0
8 0
9 0
1 0 0
%
 
I
n
t
e
n
s
i
t
y
Voyager Spec #1=>BC=>BC[BP = 10136.2, 224]
2 9 6 9 8 .8 6
2 0 9 8 8 .6 4
1 9 8 7 0 .7 0
2 9 6 7 6 .9 7
2 2 9 6 6 .8 0
2 9 5 4 6 .6 3
2 0 8 8 8 .0 4 2 3 0 6 9 .9 31 9 9 5 5 .4 5
2 8 5 1 7 .2 72 2 2 1 5 .8 7
2 0 7 8 1 .2 2 2 9 5 1 0 .2 5
1 9 3 8 8 .3 7 2 3 1 1 9 .8 7
2 0 1 0 9 .2 4 2 1 0 7 0 .0 0 2 4 5 5 6 .9 22 3 3 6 4 .1 9 2 9 2 2 6 .4 1 3 0 4 6 6 .8 1
2 1 6 8 4 .4 6 2 5 3 0 0 .9 12 0 8 6 5 .4 5 2 3 1 9 3 .0 9 3 5 1 7 8 .2 92 0 0 3 1 .3 2 2 9 3 2 6 .2 52 4 7 3 3 .8 8
3 0 5 9 8 .1 02 6 6 6 6 .5 92 0 0 7 2 .5 9 2 1 7 9 5 .4 71 9 1 8 3 .6 3 2 3 2 6 5 .8 4 2 8 7 5 9 .6 4 3 0 7 0 8 .0 82 6 5 4 2 .5 42 0 9 3 3 .8 4 2 4 2 9 4 .7 9 3 3 7 9 5 .7 32 0 0 5 8 .3 4 2 2 7 6 1 .1 12 1 9 1 0 .9 1 3 4 7 7 7 .4 3
2 8 2 3 8 .0 0 2 9 1 7 2 .1 1 3 0 6 5 8 .5 62 6 0 7 3 .1 61 9 8 3 3 .5 9 2 4 9 6 2 .8 5 3 3 6 2 8 .3 62 4 0 2 8 .6 2 2 7 3 7 7 .8 12 3 0 3 5 .4 8
2 1 6 6 6 .1 5
2 8 7 2 6 .7 12 0 3 0 2 .3 6 2 9 9 4 0 .1 72 6 9 9 9 .0 0 3 0 8 3 7 .4 82 6 1 7 3 .2 92 5 2 6 4 .8 6 3 2 9 3 7 .9 52 3 8 8 3 .2 51 9 1 5 9 .3 8 3 4 6 2 3 .7 82 2 7 2 8 .0 0 3 1 6 7 8 .8 32 1 8 2 9 .1 0
2 8 8 7 3 .4 72 7 8 5 4 .3 2 3 0 0 0 5 .2 72 6 9 6 7 .2 62 6 0 1 3 .3 2 3 1 9 5 6 .5 52 5 1 7 4 .4 8 3 2 9 7 5 .4 41 9 5 8 0 .2 4 2 4 2 7 4 .8 12 0 6 4 1 .4 2 3 4 5 3 1 .7 42 3 4 3 2 .9 7
2 8 9 1 2 .9 82 2 0 6 3 .5 6 2 8 0 1 2 .7 9 3 0 0 4 9 .4 82 7 1 7 1 .4 8 3 0 9 7 6 .5 12 6 3 7 1 .8 02 5 3 1 6 .8 1 3 3 0 8 4 .7 0 3 4 7 4 3 .6 92 3 3 2 6 .8 22 0 4 0 5 .5 8 3 2 0 8 3 .3 82 4 3 3 1 .4 21 9 3 6 9 .5 2 3 3 8 8 7 .1 8
2 0 4 2 8 .5 7
 93 
Nine of the predicted Pol d 4 trypsin restriction fragments were represented in peptides 
identified by MALDI-TOF (Figure 14).  The resulting fragments covered approximately 
38% of the Pol d 4 sequence (Table 5). 
A construct was generated for expression in E. coli that did not contain the 
propeptide sequence, non-glycosylated Pol d 4 without propeptide.  This construct was 
prepared and expressed with the same protocol used in the expression of non-
glycosylated Pol d 4 with the propeptide.  Expression products were purified by metal 
affinity chromatography and visualized by SDS-PAGE and Western blotting (Figure 15). 
Both assays showed a protein approximately 27 kDa in size, correlating with the 
calculated size of non-glycosylated Pol d 4 without propeptide (27.5 kDa).  Samples were 
evaluated by MALDI-TOF analysis (Figure 16).  A strong peak that represented a protein 
of 28,149.49 Da in size was observed.   
 Expression in E. coli systems produces protein without the post-translational 
carbohydrate, additionally, this protein may not be in the proper conformation.  
Conformation may be lost due to the harsh conditions required for protein isolation and 
purification from E. coli.  Three protocols were used in an attempt to refold the 
recombinant serine proteases, non-glycosylated Pol d 4 with and without the propeptide, 
into the correct conformation.  After each refolding attempt proteins were separated using 
benzamidine chromatography to isolate correctly folded serine proteases.   Elution from 
benzamidine chromatography was visualized by SDS-PAGE (data not shown).  Protein 
was not absorbed on the benzamidine column following each of the refolding protocols.   
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Figure 14:  MALDI-TOF mass spectrometry analysis of tryptic fragments of E. coli 
expressed Pol d 4.  Protein products from E.coli expression were purified by metal 
affinity chromatography.  Trypsin was used to digest 10 µg of protein which was then 
prepared for analysis by MALDI-TOF mass spectrometry.  Peaks at were identified at 
1554.6, 1553.6, 1589.4, 1801.7, 2290, 1669.7, 3269, and 3535 Da corresponding with the 
predicted tryptic fragments of Pol d 4. 
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Table 5:  Comparison of the tryptic fragments generated by peptide sequencing of 
non-glycosylated Pol d 4 with the propeptide to the Pol d 4 amino acid sequence.  
Non-glycosylated Pol d 4 with the propeptide was expressed and purified by metal 
affinity chromatography.  Protein was digested with trypsin and peptide fragments were 
separated using MALDI-TOF mass spectrometry.  Nine of the 20 predicted fragments 
were identified from the expression products.  The predicted peptides covered by the 
observed fragments were 3, 7, 10, 16, 17, and 19 (in red).  The sizes of the observed 
fragments are included on the table.  Those fragments with more than one peptide mass 
are the result of incomplete cleavage of the intact protein.  Peptides identified by 
MALDI-TOF mass spectrometry covered 38% of the Pol d 4 sequence.  
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        Fragment          Predicted Tryptic Fragments               MALDI-TOF Fragment (Th) 
1 
1
  EENCKCGWDNPSR  
13
  
2 
14
 IVNGVETEINEFPMVAR  
30
  
3 
31
 LIYPSPGMYCGGTIITPQHIVTAAHCLQK 
60
 3269 and 3535 
4 
61
 YKR 
63
  
5 
64
 TNYTGIHVVVGEHDYTTDTETNVTK 
88
  
6 
89
 R 
89
  
7 
90
 YTIAEEVTIHPNYNSHNNDIAIVK 
114
  
8 
115
 TNERFEYSMK 
124
  
9 
125
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Figure 15:  Evaluation of E. coli expressed Pol d 4 without the propeptide by SDS-
PAGE and Western blotting.  Expression products of E. coli expressed Pol d 4 without 
the propeptide were harvested and purified with metal affinity chromatography. The same 
amount, 15 µl, of protein was used in the SDS-PAGE and Western blot.   A. Protein 
samples were prepared and electrophoresed using SDS-PAGE.  A protein band was seen 
at approximately 27 kDa.  B.  Western blotting was performed using metal affinity 
purification products. A band was seen at approximately 27 kDa.   
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Figure 16:  MALDI-TOF mass spectrometry analysis of intact protein from E. coli 
expressed Pol d 4 without propeptide.  Harvested protein was purified from the 
expression of E. coli expressed Pol d 4 without propeptide by metal affinity 
chromatography.  A fraction of 0.1 to 10 µg of purified protein was used in MALDI-TOF 
mass spectrometry, which indicated a protein (circled) at 27,977 Da.   
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3.2  Mutation of Pol d 4 
3.2.1 Mutational analysis of Pol d 4 
 The interaction of Pol d 4 and patient IgE will supply information about the 
importance of Pol d 4 in the species specific immunologic reaction.  The major amino 
acid epitopes contribute to this type of reaction.  The epitopes found on Pol d 4 were 
predicted using CEPS.  The prediction server generated 11 possible allergenic peptides.  
A second server, IPIS, was used to predict the amino acid residues on Pol d 4 which may 
be involved in protein-to-protein interactions. The IPIS predicted 34 amino acids play a 
role in protein-protein interaction.  Both data sets were compared and aligned for 
common amino acid residues (Table 6).  The data sets had 23 amino acid residues in 
common, highlighted in red on Table 4.  The data was visualized on model of the charge 
distribution of Pol d 4 (Figure 17).  Three sets of amino acids were chosen for mutation 
based on their identification with computational models and their position on the charge 
distribution model.  The first construct had a mutational substitution in predicted epitope 
6.  Glutamine 101 was chosen for mutation and arginine 102, while not identified by the 
IPS, was also mutated based on its position in on the charge distribution model.  The 
second construct had mutational substitutions in predicted epitopes 3 and 10, within these 
epitopes histidine 42 and arginine 211 were mutated.  The last construct utilized predicted 
epitopes 1 and 8, arginine 137 and glutamine 6 were mutated to an alanine.  Mutation 
reactions were performed with the QuikChange
®
 Lightning Site-Directed Mutagenesis 
Kit, allowing for the mutation of amino acid residues in the previously generated  
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Table 6: The comparison of the amino acid residues predicted by IPIS with 
conformational epitopes predicted by CEPS.  The amino acid sequence of Pol d 4 was 
up-loaded onto CEP server and 14 potential epitopes were generated.  The same 
information was up-loaded onto the IPIS server and amino acid residues that play a role 
in protein-protein interaction were predicted.  Both data sets were compared for common 
amino acid epitopes which are labeled in red.   
 
 
 
 
 
 
 
 
 
 104 
 
 
 
 
 
 
229-EFiHNaTIGE-238 11
209-FgRTcADD-216 10
155-TREQcETHyGAAiANA-170 9
136-LRYNGQNsKV-145 8
116-FNYMTRNLTNeTvT-129 7
100-NERfEYSMK-1086
79-AEvTIhPNYNSH-90 5
64-YTTdTETNV-724
42-HcLQKYkRTNYTG-543
21-PSPGmY-26 2
3-NgVETEInEfP-13 1
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Figure 17:  Model of Pol d 4 depicting surface charges.  The molecular model was 
prepared with the SPDBV program using the previously described Pol d 4 sequence.  
Basic amino acids are labeled in blue, acidic amino acids are labeled in red, non-polar 
amino acids are labeled in yellow, and polar amino acids are labeled in grey.   
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 pFastBac:Pol d 4 construct using the Sol i 2 leader sequence.  All mutations were 
verified by nucleic acid sequencing and analysis using the GCG software package.     
3.2.2  Expression of Pol d 4 mutations 
 All Pol d 4 mutants were expressed in the baculovirus expression system to 
maintain conformation and possible post-translational glycosylation.  Expression was 
carried out in the same manner as previously described.  Small amounts of expression 
culture were purified, and expression was visualized by immunoblot using an anti hexa-
histidine tag antibody to probe for protein (data not shown). Expression in each of the 
mutants was optimal at day 2 post-infection of High Five™ cells.    
 Expression products from all three mutants were visualized by SDS-PAGE (data 
not shown).  Mutants were seen as a 42 kDa protein band.  The calculated size for 
mutants is approximately 30 kDa.  The molecular weights were determined by MALDI-
TOF (data not shown). Mut 1 and Mut 2 were seen as a broad peak at approximately 35 
kDa.  Data from Mut 4 showed a peak that ranged from 30 to 35 kDa.  Protein 
fingerprinting of the mutants showed various degrees of coverage (data not shown).  The 
mutated fragments were observed during analysis.  Mut 2 produced 8 tryptic fragments 
that aligned with the Pol d 4 sequence, representing 49% of the molecule.  Mut 2 had 4 
fragments which aligned with the Pol d 4 sequence and these covered 14% of the 
molecule.  Mut 4 had 3 fragments which aligned with the Pol d 4 sequence and covered 
25% of the entire sequence (Table 7). 
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Table 7: Evaluation of MALDI-TOF data from the expression of mutant 1, 2, and 4.  
Whole protein products from mutation expressions were purified by metal affinity 
chromatography and concentrated 5X.  Approximately 5 µg of purified protein was 
analyzed by MALDI-TOF mass spectrometry.  For each mutation, predicted and whole 
protein sizes are shown.  MALDI-TOF data showed that mutants are approximately 30-
35 kDa in size with large and broad peaks.  Similar to data gathered for recombinant Pol 
d 4.  The purified protein was digested with trypsin for each mutant.  The table lists the 
number of fragments that were matched to the Pol d 4 sequence and the percentage that 
was covered by the peptides.   
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Mutant 
Predicted    
Protein Size 
Whole 
Protein Size 
Fragments Matched 
% Sequence 
Covered 
1 29553 Da ~ 35 kDa 8 49% 
2 29553 Da ~ 35 kDa 4 14% 
4 29553 Da ~ 30-35 kDa 3 25% 
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3.3  IgE Binding to recombinant Pol d 4 
 The involvement of the amino acid sequence and the carbohydrate determinants 
on IgE binding were assayed by immunoblotting and immunoblot inhibition. These tests 
utilized sera from individuals who have varying degrees of IgE reactivity to European  
paper wasp venom, and sera from patients sensitized to North American paper wasps.  
The amount of protein blotted for each assay was verified by staining with Imperial 
protein stain.   
 The recombinant forms of Pol d 4 were purified and bound to nitrocellulose strips 
at 5 µg per immunospot.  Sera were titrated at 1:20, 1:10 and 1:5 to determine the 
optimum amount needed to visualize IgE binding.  Initial assay with the different 
titrations showed that the minimum amount of sera that could be used was a 1:5 dilution. 
Prior to the beginning immunoblot assays with all patient antigens, 2 sera was used to 
assay specific binding of patient sera to recombinant Pol d 4.   Patient sera were 
incubated with 10 µg of recombinant Pol d 4 or whole venom prior to exposure to the 
membrane bound protein in the immunoblot assay (Figure 18).  Visually, binding to 
membrane bound recombinant Pol d 4 decreased when sera was incubated with 
recombinant Pol d 4 and was completely missing when sera was incubated with whole P. 
dominulus venom. The different forms of recombinant Pol d 4 were probed with human 
sera obtained from non-allergic patients to assay non specific binding (Figure 19 ).  There 
was no significant binding to recombinant Pol d 4 from these patients’ sera.  Each strip 
was probed with one of thirteen European patient sera, with varying degree of IgE 
reactivity to P. dominulus venom (Table 8).  Sera from a second set of European patients 
sensitized to paper wasp  
 111 
   
 
 
 
 
 
 
 
Figure 18:  Immunoblot inhibition with soluble antigen.  European patient serum 3 
and American patient serum 2 were used for immunoblot inhibition with soluble antigen. 
All sera were used at a dilution of 1:5.  Recombinant Pol d 4 (A), mutant 1 (B), mutant 2 
(C), mutant 4 (D) and whole venom (E) were blotted onto the membrane at a 
concentration of 5µg.  The European patient 3 serum (1), European patient 3 serum + 10 
µg recombinant Pol d 4 (2) , European patient 3 serum + 10 µg whole venom (3), 
American patient 2 serum (4), American patient 2 serum + 10 µg recombinant Pol d 4 
(5), and American patient 2 +  10 µg whole venom (6) were the treatments. 
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Figure 19:  Immunoblot assay with negative patient sera.   Negative patient sera 1 and 
2 were diluted 1:5 and used for immunoblot.  Recombinant Pol d 4 (A), mutant 1 (B), 
mutant 2 (C), mutant 4 (D) and whole venom (E) were blotted onto the membrane at a 
concentration of 5µg.  There was no significant IgE binding detected. 
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Table 8:  List of IgE antibody levels of European patient sera to venom from P. 
dominulus.  Thirteen sera from patients sensitized to European paper wasps were assayed 
by RAST for IgE specific for the venom components.  Patients with RAST score 2 (0.7-
3.49 i.v. IgE level) has a moderate level of allergen-specific IgE, RAST score 3 (3.5-
17.49 i.v. IgE level) has high level of allergen-specific IgE, RAST score 4 (17.5-49.49 
i.v. IgE level) has very high levels of allergen-specific IgE.   
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1  13.6 
2  9.1 
3  2.1 
4  3 
5  36.6 
6  49.5 
7  21.5 
8  14.7 
9  47.5 
10  21.1 
11  15.5 
12  40.5 
13  7.1 
 
 
 
 
Patient Number IgE Antibody Level                   
(KU/L) 
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were also assayed.  Visually all sera contained IgE that bound to the P. dominulus venom 
extract.  Binding of IgE, from the first set of patient sera, to different forms of 
recombinant Pol d 4 were assayed by immunoblot (Figure 20).  IgE bound to the 
recombinant glycosylated form of Pol d 4 in 61.5% of the sera tested.  Mutant 1 and 2 
each bound IgE from 54% of patients, while mutant 4 bound IgE from 46% of patients.   
The whole venom control bound IgE in 11 of the 13 patients (85%) and the native 
protease bound IgE in a total of 9 patients (69%).  A second set of European patient sera 
contained four patients and were used to assay IgE binding to the various forms of Pol d 
4 (Figure 21). Visually the baculovirus expressed form of Pol d 4 bound IgE in 100% of 
the sera.  All three mutants bound IgE from patients 2, 3, and 4 (75%).  The whole venom 
bound IgE in 3 of the 4 sera (75%), the exception being patient 2.  The second set of 
European patient sera had 100% of IgE bind the native protein.  Finally, the recombinant 
proteins were assayed with two sera from patients who had previously tested negative 
against vespid venom (data not shown).  The immunoblot using the negative sera did not 
have visible IgE binding. 
  In order to compare IgE binding to the recombinant forms of Pol d 4 a 
densitometric analysis of each immunospot was performed.  Seventeen patients in total 
were assayed and the data for recombinant Pol d 4 (rPol d 4), mutants 1, 2, and 4, whole 
venom control and native Pol d 4 is reported in Figure 22.   The standard deviation for 
each protein immunospot was calculated and averaged.  The standard deviations are as 
follows: rPol d +/- 65%, mutant 1 +/- 54%, mutant 2 +/- 64%, mutant 4 +/- 71%, and 
whole venom +/- 73%.  The whole venom control and native Pol d 4 had an average of 
1.1 x 10
6
 and 1.3 x10
6
 INT/mm
2
 respectively.  The baculovirus expressed Pol d 4  
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Figure 20:  Immunodetection of IgE binding to various forms of recombinant Pol d 
4 with sera from patients allergic to European paper wasps.  Sera (1:5) from patients 
previously identified with positive IgE binding reactions to European paper wasps were 
used to assay IgE binding to recombinant forms of Pol d 4. Two replications were 
performed with 40% of the patient sera and one with remaining sera. Patients were 
numbered 1-13.  The recombinant forms of Pol d 4 were blotted at a concentration of 5 
µg per spot.  The proteins blotted were: baculovirus expressed recombinant Pol d 4 (A), 
mutant 1 of Pol d 4 (B), mutant 2 of Pol d 4 (C), and mutant 4 of Pol d 4 (D).    Whole 
venom (E) and native Pol d 4 (F) were used as controls. 
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Figure 21: Immunodetection of IgE binding to various forms of recombinant Pol d 4 
with a second set of sera from patients sensitized to European paper wasp.  
Sera(1:5), from patients previously identified with positive IgE binding to European 
paper wasps, were used to assay IgE binding. One replication was performed. Patients are 
numbered 1-4.  The recombinant forms of Pol d 4 were spotted at a concentration of 5 µg 
and are: baculovirus expressed recombinant Pol d 4 (A), mutant 1 of Pol d 4 (B), mutant 
2 of Pol d 4 (C), and mutant 4 of Pol d 4 (D).    Whole venom (E) and native Pol d 4 (F) 
were used as controls. 
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Figure 22:  Densitometric analysis of the IgE binding of 17 European patient sera to 
four forms of recombinant Pol d 4.  Two sets of patient sera were used densitometric 
analysis.  The first included immunoblots using 13 European patients (1-13), with RAST 
reactivity recorded, and the second set included four additional European patients (14-
17).  The densities for baculovirus expressed recombinant Pol d 4, mutant 1 of Pol d 4, 
mutant 2 of Pol d 4, mutant 4 of Pol d 4, whole venom, and native Pol d 4 were graphed.   
The standard deviation for the recombinant forms of Pol d 4 are: +/- 65% for baculovirus 
expressed recombinant Pol d 4, +/- 54% for mutant 1 of Pol d 4,  +/- 64% for mutant 2 of 
Pol d 4, +/- 71% for mutant 4 of Pol d 4, and +/- 73% for whole venom. One-way 
ANOVA analysis of IgE binding showed that there was no significant difference between 
each group of protein. 
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immunospots had an average of 3.8 x 10
6
 INT/mm
2
 for all 17 sera assayed.  Patient 3 had 
the highest value while patient 7 had the lowest.  The highest average density for the 
mutants was in response to mutant 3 at 7.3 x 10
5 
INT/mm
2
, while the lowest average 
density was to mutant 2 at 5.7 x 10
5
 INT/mm
2
. The average density of mutant 1 was 6.1 x 
10
5
 INT/mm
2
.  The lowest density values for all three mutants were observed from 
patient 8.  Patient 1 had the highest density values to mutants 1 and 4, while the highest 
for mutant 2 was patient 3.   The densitometric data obtained from assays with European 
patient sera was used to assay the differences in IgE binding to the various recombinant 
proteins by one-way ANOVA.  The statistical test showed that there was no significant 
difference in between patient sera. 
 Three sera from American patients were used to assay IgE binding to the various 
forms of recombinant Pol d 4 (Figure 23).  These patients have been shown to have 
reactivity with other Vespids.  Visually the baculovirus expressed form of Pol d 4 bound 
66% of the sera.  Patients 2 and 3 had IgE that bound to mutants 1, 2, and 4.  The whole 
venom and native Pol d 4 bound IgE from all patient sera.   The densitometric values 
were collected for the American patient immunoblots and are shown in Figure 24.  The 
average IgE binding for the controls, whole venom and native Pol d 4, was 6.6 x 10
5
 and 
8.2 x 10
5
 INT/mm
2 
respectively.  The highest density values for recombinant Pol d 4 and 
the three mutated forms were seen in response to sera from patient 2.  The average 
binding to rPol d 4 was 1.8 x 10
6
 INT/mm
2
, mutant 1 was 1.6 x 10
6
 INT/mm
2
, mutant 2 
was 1.67 x 10
6
 INT/mm
2
, and mutant 4 was 1.8 x 10
6
 INT/mm
2
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Figure 23:  Immunodetection of IgE binding to various forms of recombinant Pol d 
4 with sera from patients sensitized to American paper wasp.  Sera from patients 
previously identified with positive IgE binding to American paper wasp venom were used 
to assay binding to various forms of recombinant Pol d 4.  Sera were diluted 1:5.  Patients 
were numbered 1-3.  Each protein was spotted at concentration of 5 µg.  The recombinant 
forms of Pol d 4 represented are: baculovirus expressed recombinant Pol d 4 (A), mutant 
1 of Pol d 4 (B), mutant 2 of Pol d 4 (C), and mutant 4 of Pol d 4 (D).    Whole venom (E) 
and native Pol d 4 (F) were used as controls.    Only one replication was performed using 
all of the sera. 
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Figure 24:  Densitometric analysis of three American sera IgE binding to four forms 
of recombinant Pol d 4.  Three sera from American patients sensitized to American 
paper wasp venom were used to assay IgE binding to the recombinant forms of Pol d 4.    
The densities for baculovirus expressed recombinant Pol d 4, mutant 1 of Pol d 4, mutant 
2 of Pol d 4, mutant 4 of Pol d 4, whole venom, and native Pol d 4 were graphed.  Due to 
the limited amount sera available only one replication was performed with all the patient 
sera.   
 
 128 
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
1 2 3
Patient Sera
D
e
n
s
it
y
 (
IN
T
/m
m
2
 i
n
 m
il
li
o
n
s
)
rPol d 4
Mutant 1
Mutant 2
Mutant 4
Whole Venom
Native Pol d 4
 129 
In an attempt to assay the presence of CCD in IgE binding from different European 
patient sera, the carbohydrate specific IgE was inhibited with bromelain.  This assay 
utilizes bromelain as inhibitor, a set of highly glycosylated cysteine proteases isolated 
from pineapple, to occupy cross-reactive carbohydrate-specific IgE.  The sera used in this 
assay were selected from the results of the previous immunoblot.   The patient sera used 
were; European patients 5, 8, 9, 10, and 11 to assay the change in IgE binding to rPol d 4 
during inhibition assays.  The sera was incubated with 1 mg/ml of bromelain prior to 
incubation with membrane bound recombinant Pol d 4.  Immunoblots are shown in 
Figure 25.  The strongest IgE binding among the immunoblot inhibition samples was 
seen in patient 8, while the lowest was seen from patient 11.   
3.4  Cloning of Pol g 4 
 The cDNA of Pol g 4 was cloned and one was used to evaluate identity with the 
known cDNA sequence and the derived protein sequence of Pol d 4.  The resulting 
sequence consists of 277 nucleic acids.  The sequence was obtained from an independent 
PCR, a second PCR reaction was not obtained to account for possible polymerase 
mutations.  A BLAST search was performed with the Pol g 4 sequence, with the most 
closely related sequence being the allergenic venom serine protease from P. dominulus.  
The aligned sequences had 96% identity (Figure 26).  
 The nucleic acid sequence was translated and characterized with the BLAST 
application on the NCBI website.  The amino acid sequence was placed in a trypsin-like 
superfamily.  A 12 amino acid propeptide was identified upstream of the mature 
molecule.  A propeptide cleavage site was identified ending at isoleucine 15.  The three  
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Figure 25:  Inhibition immunoblot assay of IgE binding to recombinant Pol d 4.   
The purified recombinant proteins were spotted at a concentration of 5 µg and all human 
sera was diluted 1:5.  The blots of baculovirus expressed recombinant Pol d 4 (A) and 
whole venom (B) were probed with sera from European patients (5, 8, 9, 10, and 11). 
Inhibition assays were used to identify the possible involvement of carbohydrate-specific 
IgE in IgE binding to recombinant Pol d 4.   Prior to incubation with the membrane 
bound proteins, the sera and a horse sera control (Con) was incubated with 1 mg/ml of  
Bromelain to compete for CCD specific IgE.  The inhibition reaction was used to probe 
recombinant Pol d 4 (C) and whole venom (D).  Only one replication of this assay was 
performed. 
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Figure 26:  Alignment of the Pol g 4 cDNA sequence with the Pol d 4 cDNA 
sequence.   The Pol g 4 sequence was cloned from mRNA and characterized by nucleic 
acid sequence.  Only one clone was evaluated.  Pol g 4 (top) and Pol d 4 (bottom) cDNA 
sequences were aligned with BLAST via the NBCI website.    Identity is indicated with a 
line (I).  The sequences were 96% identical. 
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Pg4 GGAAGAAAATTGTAAATGTGGCTGGGAAAATCCGTCGAGAATAGTAAATGGTGTTGAAAC         
||||||||||||||||||||| ||||| |||||||||||||||||||||||||||||||| 
Pd4 GGAAGAAAATTGTAAATGTGGGTGGGATAATCCGTCGAGAATAGTAAATGGTGTTGAAAC   
 
AGAAATAAATGAATTTCCCATGGTGGCACGTTTAACATATCCATCAGCAAGATAT-TATT   
|||||| ||||| |||||||||||||||||||||| |||||||||| || || || |||| 
AGAAATCAATGAGTTTCCCATGGTGGCACGTTTAATATATCCATCACCAGGA-ATGTATT   
 
GTGGTGGTACCATAATAACACCACAACATATAGTAACTGCTGCTCATTGTCTTCAAAAAT   
|||||||||||||||||||||| ||||||||||||||||||||||||||||||||||||| 
GTGGTGGTACCATAATAACACCGCAACATATAGTAACTGCTGCTCATTGTCTTCAAAAAT   
 
TTACAAGAACCAATTATACCGGTATACAGGTAATTGTTGGTGAACACGATTATACGACAG   
|| |||||||||||||||||||||||| ||| |||| |||||||||||||||||||||| 
ATAAAAGAACCAATTATACCGGTATACATGTAGTTGTCGGTGAACACGATTATACGACAG   
 
ATACGGAAACAAATGTGACCAAACGTTATACTATTGCGGAAGTAATTATACATCCGAATT   
||||||||||||||||||||||||||||||||||||||||||||| |||||||||||||| 
ATACGGAAACAAATGTGACCAAACGTTATACTATTGCGGAAGTAACTATACATCCGAATT   
 
ATAGTTCTCATATTAATGATATTGCAATTGTTAAAACAAATGAAAGATTTGAATATTCGA   
||| |||||||| ||||||||||||||||||||||||||||||||||||||||||||||| 
ATAATTCTCATAATAATGATATTGCAATTGTTAAAACAAATGAAAGATTTGAATATTCGA   
 
TGAAAGTTGGACCAGTTTGTCTTCCATTTAATTATATGACTCGAAATTTAACTAACGAGA   
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
TGAAAGTTGGACCAGTTTGTCTTCCATTTAATTATATGACTCGAAATTTAACTAACGAGA   
 
CTGTAACAGCATTAGGTTGGGGTAAATTAAGGTATAATGGTCAAAATTCAAAGGTTTTAA   
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
CTGTAACAGCATTAGGTTGGGGTAAATTAAGGTATAATGGTCAAAATTCAAAGGTTTTAA   
 
GAAAAGTTGATTTGCACGTAATTACAAGGAAACAATGTGAAACACATTATGGAGCAGCTA   
||||||||||||||||||| ||||||||| |||||||||||||||||||||||||||||| 
GAAAAGTTGATTTGCACGTTATTACAAGGGAACAATGTGAAACACATTATGGAGCAGCTA   
 
TTGCAAATCCGAACTTACTTTGTACGTTTGACGTTGGAAGGGATGCTTGTCAGAACGATA                             
|||||||| |||||||||||||||||||||| |||||||||||||||||||||||||| |  
TTGCAAATGCGAACTTACTTTGTACGTTTGATGTTGGAAGGGATGCTTGTCAGAACGACA   
 
GTGGTGGTCCAATATTATGGAGAAGTCCAACTACAGATAATTTAATTCTCGTTGGTATAG         
|||||||||||||||||||||||||||||||||||||||||||||||||||||||| ||| 
GTGGTGGTCCAATATTATGGAGAAGTCCAACTACAGATAATTTAATTCTCGTTGGTGTAG   
 
TTAGTTTTGGTAGAACCTGTGCAGATGATGCACCAGGTGGTAATGCAAGGGTCACCAGTT   
||| |||||||||||||||||||||||||||||| ||||||||||||||||||||||||| 
TTAATTTTGGTAGAACCTGTGCAGATGATGCACCTGGTGGTAATGCAAGGGTCACCAGTT   
 
TTATGGAATTTATTCATAACGCTACAATCGGAGAAACATACTGCAAGGCGGATTAA   
|||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
TTATGGAATTTATTCATAACGCTACAATCGGAGAAACATACTGCAAGGCGGATTAA   
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amino acids of the active site were identified, histidine 45, asparagine 140, and serine 
260.  The substrate binding site consists of asparagine 202, serine 275, and glycine 224.    
A search of the NCBI protein database showed that the amino acid sequence was most 
closely related to Pol d 4 (Figure 27).  The search demonstrates that the Pol g 4 amino  
acid sequence was most closely related to the Pol d 4 amino acid sequence (96%) 
followed by an anticoagulant serine protease from Vespa magnifica (52%), venom 
protein from Nasonia vitripennis (44%), venom serine protease from Apis mellifera 
(42%), and a trypsin-like protease from Anthonomus grandis (42%).  Models of Pol d 4 
and Pol g 4 were generated, using SWISS-MODEL which showed similar structure and 
substrate binding sites (Figure 28).  However, there are some notable amino acids 
changes between the two molecules.  The change of alanine (23) to a proline is a 
significant change within the structure of the molecule.  Also, the substitution of a 
glutamic acid at position 158 (lysine) in Pol d 4 alters the local charge and extends a α-
helix in the Pol g 4 model.   
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Figure 27:  Comparison of the derived Pol g 4 and Pol d 4 amino acid sequences.  
Nucleic acid sequences for Pol g 4 and Pol d 4 were used to obtain amino acid sequences 
using GCG.  The derived amino acid sequence for Pol g 4 (top) was compared with the 
sequence of Pol d 4 (bottom) using NCBI program BLASTn.  The middle sequence 
shows the amino acids in common between both sequences, the + indicates amino acid 
similarity and a blank space denotes a difference in charge.  These sequences share 96% 
identity.     
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Pg4 EENCKCGWENPSRIVNGVETEINEFPMVARLTYPSARYYCGGTIITPQHIVTAAHCLQK   
EENCKCGW+NPSRIVNGVETEINEFPMVARL YPS   YCGGTIITPQHIVTAAHCLQK 
Pd4 EENCKCGWDNPSRIVNGVETEINEFPMVARLIYPSPGMYCGGTIITPQHIVTAAHCLQK   
 
FTRTNYTGIQVIVGEHDYTTDTETNVTKRYTIAEVIIHPNYSSHINDIAIVKTNERFEYS 
+ RTNYTGI V+VGEHDYTTDTETNVTKRYTIAEV IHPNY+SH NDIAIVKTNERFEYS 
YKRTNYTGIHVVVGEHDYTTDTETNVTKRYTIAEVTIHPNYNSHNNDIAIVKTNERFEYS   
 
MKVGPVCLPFNYMTRNLTNETVTALGWGKLRYNGQNSKVLRKVDLHVITRKQCETHYGAA   
MKVGPVCLPFNYMTRNLTNETVTALGWGKLRYNGQNSKVLRKVDLHVITR+QCETHYGAA 
MKVGPVCLPFNYMTRNLTNETVTALGWGKLRYNGQNSKVLRKVDLHVITREQCETHYGAA   
 
IANPNLLCTFDVGRDACQNDSGGPILWRSPTTDNLILVGIVSFGRTCADDAPGGNARVTS   
IAN NLLCTFDVGRDACQNDSGGPILWRSPTTDNLILVG+V+FGRTCADDAPGGNARVTS 
IANANLLCTFDVGRDACQNDSGGPILWRSPTTDNLILVGVVNFGRTCADDAPGGNARVTS   
 
FMEFIHNATIGETYCKAD   
FMEFIHNATIGETYCKAD 
FMEFIHNATIGETYCKAD   
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Figure 28:  Super position of the molecular models of Pol d 4 and Pol g 4.  Models of 
Pol d 4 (green) and Pol g 4 (turquoise) were generated using SWISS-MODEL.  The 
models were superimposed using PVPDB viewer.  Two notable substitutions between the 
two serine proteases are highlighted.  The two changes are from (A) glutamic acid (Pol d 
4) to lysine (Pol g 4) and (B) proline (Pol d 4) to alanine (Pol g 4). 
 
 
 
 
 
 
                       
 
 
  
 138 
 
 
 
 
 
A
B
 
 
 
 
 
  
Chapter 4:  DISCUSSION 
  The cross-reactivity between European and American paper wasp venom 
allergens has been shown to be partial.  The allergenic serine protease isolated from 
European paper wasp venom has been identified as an important venom allergen 
(Sanchez et al., 1995, Pantera et al., 2003, and Winningham et al., 2004).  The 
identification of allergenic epitopes on Pol d 4 will provide data that will be important in 
determining the role of Pol d 4 in the partial cross-reactivity between paper wasp groups.  
During characterization of baculovirus expressed recombinant of Pol d 4, evidence 
indicated that it may be heterogeneously glycosylated.  The E.coli expressed recombinant 
form of Pol d 4 was unsuccessfully refolded.  Immunoblot assay results of various forms 
of recombinant Pol d 4 contain amino acid epitopes and possibly CCD.  Lastly, the 
nucleic sequence for Pol g 4 had high identity to the Pol d 4 sequence, supporting the 
evidence that the two molecules bind the same amount of IgE.   
4.1 Analysis of the production of recombinant Pol d 4 
 In order to evaluate IgE binding to Pol d 4, the protein was expressed in a 
baculovirus and E. coli system.  The previously reported nucleic acid sequence was 
used for expression. 
4.1.1 Eukaryotic expression of Pol d 4 
 Recombinant protein expression is widely used to produce proteins from a variety 
of sources.  Expression of target proteins allow for the production of large amounts 
without the laborious tasks of insect collection, protein isolation, and extensive 
purification. A variety of cell lines, both eukaryotic and prokaryotic are used with 
associated expression vectors.  Typically, proteins derived from insects are expressed in 
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either a baculovirus or bacterial expression system.  Allergens produced in the 
baculovirus systems can retain native conformation, bioactivity, and IgE reactivity.  This 
is due to similarities in protein processing, such as, glycosylation and conformational 
folding.  In addition, this system allows the use of native leader sequences for the 
secretion of target proteins resulting in easier purification.   
 The baculovirus expression system was chosen for expression of a recombinant 
form of Pol d 4 which would be similar to native Pol d 4.  Several laboratories have 
reported the successful expression of insect venom allergens in this type of system (King 
et al., 1996, Schmidt et al., 1996, Schmidt et al., 2003, and Soldatova et al., 2007).     
Glycosylation is essential for proper folding of some proteins.  Additional research has 
shown that carbohydrates may have an important role in IgE binding to this venom 
allergen and investigation of IgE epitopes must include carbohydrate (Hemmer et al., 
2001, Bencurova, 2004, Hemmer et al., 2004, and Chensheng, 2008).   
 Analysis of recombinant Pol d 4 produced in the baculovirus system yielded a 
protein that was larger in size than the calculated size.  Mass spectrometry analysis of the 
intact recombinant protein confirmed the molecular weight observed with SDS-PAGE 
and western blotting. The difference in size between the recombinant protein and the 
calculated molecular weight of Pol d 4 could possibly be the result of post-translational 
modification of the expressed protein.   
 Evidence obtained during the characterization of the product of expression in Pol 
d 4 in a baculovirus system may indicate that it maybe glycosylated.  An increase in 
protein molecular weight due to glycosylation has been observed in many proteins.  An 
example of an increase in molecular weight by glycosylation is Bothrops (snake) protease 
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A, a serine protease in the same family as Pol d 4.  Studies have shown carbohydrate 
accounts for 62% of the molecular weight of the native form of Bothrops protease A 
(Nobuhiro et al., 2003 and Leme et al., 2008).  Analysis of the amino acid sequence of 
Pol d 4 showed the presence of six potential N-glycosylation sites (Fitch et al., 2000 and 
Winningham et al., 2004) and two to four of these sites appear to be glycosylated in the 
native form. During mass spectrometric analysis of tryptic peptide fragments only three 
of the six glycosylation sites were present on the observed fragments, suggesting if the 
recombinant protease is glycosylated it would be limited to three of the sites.   
 The change in mass and charge maybe contributed to the several post-
translational modifications.  Recombinant proteins can undergo several modifications, 
such as, acetylation, phosphorylation, alkylation, and glycosylation which may not mimic  
modifications observed in the native protein.  For example, Du et al. (2005) have shown 
that phosphorylation of serine residues in histidine-tag sequence can cause heterogeneity 
in mass of an expressed kinases.  While our construct does not contain serine residues in 
the histidine-tag, a phenomenon such as this may affect the size of our recombinant 
protein and should be investigated to verify glycosylation of the recombinant serine 
protease. 
   The difference in size and charge when observing the baculovirus expressed 
recombinant form of Pol d 4 may be caused by different factors.  Differential 
glycosylation has been observed in proteins expressed in Sf9 (Mannberg et al., 1992 and 
Percival et al., 1997).    The initial expression and evaluation of the glycosylated 
recombinant form of Pol d 4 was performed in Sf9 cells.  The recombinant protein 
expressed in the High Five™ cell line show similar properties suggesting that these 
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proteins could contain the same type of modification.  The differential charge may be 
attributed to an artifact of expression in the Sf9 cell line.  Studies of the enzyme activity 
of recombinant proteins which have heterogeneous carbohydrates show that this may not 
affect enzymatic activity.  However, the heterogeneous glycosylation of Pol d 4 may 
affect the binding of carbohydrate-specific IgE.    
4.1.2 Prokaryotic expression of Pol d 4 
 The use of E. coli-produced recombinant allergens in immunotherapy has become 
of interest in the treatment of insect allergy.  These expression systems are efficient and 
cost effective methods of generating large amounts of target protein.  An advantage of 
this system is the ability to manipulate recombinant proteins to be efficient at stimulating 
the immune system without causing an allergic reaction.  However, proteins produced in 
these systems lack the post-translational modifications typical of eukaryotic expression 
systems.  Without these modifications the proteins could retain or lack proper structure.  
The binding of IgE to proteins expressed in these systems must be assayed for their 
ability to bind IgE.    
 Pol d 4 was produced in the E. coli system in an attempt to assay the binding of 
IgE to a non-glycosylated form of the serine protease.  The purification of recombinant 
proteins showed that E. coli expressed recombinant form of Pol d 4 did not retain native 
conformation.   Several protocols were used to re-fold the recombinant proteins into 
native conformation, however, these attempt failed to yield a protein that bound to 
benzamidine.  
 The lack of apparent conformation of the prokaryotic-expressed recombinant Pol 
d 4 may have been influenced by a number of factors.  First, the harsh conditions needed 
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for purification of proteins within inclusion bodies can have an irreversible effect on 
disulfide bond formation.  The various protocols used in this study to re-fold recombinant 
Pol d 4 utilized redox reagents to encourage the formation of disulfide bonds.  Second, 
the lack of glycosylation typical of this type of expression system may have an important 
effect on the conformation of the recombinant protein.  King et al. (1996) has shown that 
a recombinant allergen produced and re-folded in a prokaryotic system has the ability to 
bind IgE from sensitized patient sera.  However, hyaluronidase isolated from Vespula 
genus, lacks post-translational carbohydrates.  The absence of carbohydrate may have 
made the re-folding of this protein difficult due to their influence on protein 
conformation.  Seppala et al., (2009) has shown the importance of carbohydrate on the 
conformation of another allergen, hyaluronidase. Studies with this molecule showed that 
when carbohydrate was enzymatically stripped it loses native conformation (Seppala et 
al., 2009).  The attempts at re-folding both prokaryotic expressed Pol d 4 constructs may 
have been influenced by the lack of post-translational modifications. Finally, re-folding 
of recombinant Pol d 4 produced in the prokaryotic system might be possible using a 
different protocol.  Numerous re-folding protocols are available in the literature; the 
protocols that were chosen may not have been optimal for the re-folding of Pol d 4.     
4.1.3 Epitope analysis of Pol d 4 
 Data suggests native Pol d 4 contains both carbohydrate and amino acid allergenic 
epitopes.  The amino acid epitope most likely confers species-specific immunologic 
reactiveness and clinical significance.  In order to investigate the role of Pol d 4 in the 
partial cross-reactivity between European and American paper wasp venom allergens, the 
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potential allergenic amino acid epitopes were identified, mutated, and assayed for IgE 
binding.    
 The determination of allergenic epitopes can be accomplished by different means.  
The first and most reliable is the visualization of IgE binding by x-ray diffraction of 
crystals.  This method shows the structure of the molecule, and where and how IgE binds 
to that allergen. This technique requires large amounts of pure protein samples, and IgE 
from sensitized patients, as well as, an array of equipment and expertise.  Several 
laboratories have used peptide fragments which cover the sequence of the protein of 
interest.  These peptides are probed with IgE, and fragments which bind the IgE can be 
used to aid in determining the major allergenic epitopes.  However, allergenic epitopes of 
venom allergens are largely conformational.  Monoclonal antibody inhibition has been 
used to map allergenic epitopes.  The antibodies are generated against major epitopes, 
then used to assay the binding of IgE to the allergen of interest.  This method requires the 
generation of monoclonal antibodies which can be time consuming and expensive.  
Further, the identification of epitopes requires a crystal structure or structural information 
about similar allergens. Finally, epitopes can be predicted by computational analysis.  We 
predicted epitopes by use of a completed molecular model then mutated, expressed, and 
evaluated IgE binding to the protein.    
 Predicted epitopes on Pol d 4 were evaluated for potential allergenic IgE epitopes.  
The prediction servers typically use models to locate the epitopes. There is no crystal 
structure available for Pol d 4 or a similar insect serine protease.  Three constructs were 
produced, each containing mutations in two epitopes.    Studies utilizing mutagenesis of 
allergenic epitopes have shown that the change of one amino acid can be sufficient to see 
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a significant drop in IgE binding (Burks et al., 1997 and Beezhold et al., 2003). Selected 
amino acids were mutated to alanine. The alanine residue is neutral and supports the 
formation of α-helices and β-pleated sheets to aid in maintaining protein conformation 
(Rabjohn et al., 1999).  The substitution of an amino acid may change the conformation 
of the protein in areas other than the targeted epitopes.  These changes were not assayed 
and have to be considered when evaluating the IgE binding data for the recombinant 
mutants of Pol d 4.  The changes in the selected epitopes were used to study epitopes that 
bind IgE on Pol d 4.       
4.2 Analysis of IgE binding to the recombinant and mutated forms of Pol d 4 
   Partial cross-reactivity between venom allergens of European and North 
American paper wasps has been documented (Winningham et al., 2003).  Other studies 
have shown that immunotherapy with North American paper wasp venom may confer 
only partial protection to patients sensitized by European paper wasps (Bonadonna et al., 
2007).  The hyaluronidase and phospholipase A1B have shown high amounts of cross-
reactivity, therefore, they may not be important in species-specific immune response 
(Hoffman, 1981, Hoffman and McDonald, 1983, Hoffman, 1985, Hoffman, 1986, 
Jacobson et al., 1992, and Lu et al., 1995). Antigen 5 and the serine protease may play an 
important role in species-specific immunologic reactions to venom of European and 
North American paper wasps (King and Spangfort, 2000, Pantera et al., 2003, King and 
Guralnick, 2004, Winningham et al., 2004, and Hoffman, 2006).  
 Studies with the isolated venom serine protease from each species group showed a 
distinct pattern of IgE binding from patients sensitized to different paper wasp groups.  
Winningham et al. (2003) showed the serine protease from European and North 
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American paper wasps bind IgE from sera of American and European sensitized patients.  
However, the presence of a competitor significantly decreased the binding of IgE North 
American serine protease, while binding the European protease continued to be present.  
These results suggest carbohydrate and amino acid epitopes may be present on the 
allergenic serine protease isolated from European paper wasps.   
 The binding to amino acid and carbohydrate epitopes were evaluated by 
immunoblotting.  This method, while convenient, has several limitations.  The 
immunoblot assay, unlike western blotting, does not require denaturing conditions, 
allowing the recombinant proteins to maintain conformation.  However, the absence of 
protein seperation makes it difficult to ascertain the size of the protein being bound by 
IgE and reducing the amount of background binding that may occur because of 
contaminating proteins.  In addition, immunoblotting may result in non-uniform binding 
of IgE to the recombinant Pol d 4 due to unequal exposure to the sera which may cause 
false negative results.  Also, unlike other means of assaying protein binding to 
immunoglobulin, such as ELISA, assaying the colometric changes is difficult due to 
several factors.  The different exposure times of the IgE:protein complex to the substrate 
may result in a higher or lower densitometric reading and an increase in background.  In 
the described assays, a relatively large concentration of sera and recombinant was used.  
Titration of sera showed that the 1:5 dilution of patient sera was optimal to visualize IgE 
binding.  The amount of protein was chosen due to the presence of impurities consistently 
found in the purification of Pol d 4 recombinant proteins.  Both concentrations were used 
in order to account for the small amount of IgE, approximately 5 x 10
-5 
mg/ml found in 
human sera.   
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 Imumunoblot was used to assay recombinant and three mutants of Pol d 4 for IgE 
binding.  In addition to the recombinant proteins, a whole venom control was used.  This 
control was used to verify the reactivity of patient sera to venom allergens.  This control 
was used to verify the results of the RAST on the European sera and to visualize the 
binding of IgE in the other sera to something contained within the venom.  A second 
control, the native serine protease isolated from P. dominulus venom via benzamidine, 
was used to visualize the binding of patient IgE to the native Pol d 4 allergen.  The native 
Pol d 4 was several years old and may have been proteolyzed.  The degradation of this 
protein may account for the atypical and inconsistent immunoblot results with this 
protein.    
 The two recombinant forms of Pol d 4 produced in the prokaryotic expression 
system were assayed for IgE binding with sera from patients sensitized to European paper 
wasps.    Initially, assays using the two prokaryotic forms of Pol d 4 showed that patient 
IgE did not bind to either recombinant protein (data not shown).  The lack of IgE binding 
to both of the prokaryotic proteins suggests two factors may have influenced the epitopes 
on Pol d 4.  The IgE may be binding to carbohydrates present on the recombinant 
proteins.  Prokaryotic expression of both Pol d 4 constructs would lack these 
modifications.  Secondly, amino acid epitopes on insect allergens are typically 
conformation dependent.  The lack of post-translational carbohydrate and the conditions 
needed for purification may interfere with disulfide bonding and therefore may have 
interfered with protein conformation.  
 The glycosylated form of recombinant Pol d 4 and all three mutants were 
evaluated for their ability to bind IgE from sera of 17 patients previously assayed for 
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reactivity to European paper wasp venom (Table 9).  The majority of patient sera bound 
to the whole venom control with the exception of one.  The lack of binding to the venom 
control suggests that IgE specific for the CCD may not be present in this serum but 
binding to native Pol d 4 suggest IgE specific to that molecule. Since the allergenic serine 
protease is a minor component of the whole venom, approximately 3%, this patient may 
not have IgE specific for the major allergens in the venom, causing decreased detection 
of IgE binding to the whole venom control.  Sera with IgE that did not bind the 
baculovirus expressed form of Pol d 4, did have IgE which bound to P. dominulus 
venom.  The lack of IgE binding in these patients suggests that IgE from these patients 
may be specific for other allergens found in the venom.  One of these, Patient 6, had a 
high reactivity to P. dominulus venom of 49.5 KIU/ml, however, no binding to the 
baculovirus expressed recombinant form of Pol d 4, and marginal binding to the three 
mutant forms.  This type of IgE binding indicates that a high degree of reactivity does not 
predict binding to a given allergen within the venom.   
 Immunoblots of the mutants were analyzed to evaluate the importance of the 
predicted IgE epitopes on binding.  One patient had IgE bind to mutant 4 but not to the 
remaining recombinant form of Pol d 4.  This type of binding pattern suggests that the 
mutation may influence protein conformation, exposing additional epitopes.     
 Evidence of major epitopes within Pol d 4 can be determined by the lack of IgE 
binding to the mutated forms of recombinant Pol d 4.  Visually, mutant 1 bound the least    
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Table 9:  The binding patterns of IgE from P. dominulus sensitized sera to multiple 
recombinant forms of Pol d 4.  The reactivity of  the first 13 European patients and the 
second set of European patients (14-17) are listed along with the binding of patient IgE to 
various forms of recombinant Pol d4 IgE binding was assayed on glycosylated Pol d 4 
(Pol d 4), E. coli expressed recombinant form of Pol d 4, three mutant forms of Pol d 4 
(mutant 1, mutant 2, and mutant 4), whole venom extract, and native Pol d 4.  Negative 
IgE binding (-), marginal binding (+/-), binding (+), and strong binding (++) are indicated 
for each serum. 
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Patient Reactivity rPol d 4       Mutant 1     Mutant 2       Mutant 4 Whole            Native  
Sera Venom Protease
1
2
3
4
5
6
7
8
9
10
11
12
13
13.6
9.1
2.1
3
36.6
49.5
21.5
14.7
47.5
21.1
15.5
40.5
7.1
+/-
-
+
-
-
+/-
+/-
-
-
-
-
+
+
+
+
+
+
+
-
-
-
+
-
-
+
+
+/-
-
++
-
+
+/-
-
-
-
-
-
+
+
-
-
-
-
+
+/-
+
-
+
-
-
+
+
++
+
+
+
+/-
++
+
+/-
+
+/-
+
+
+
+/-
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
++
-
+
+
-
+
+
+
-
+
+
+
-
+
+
+
-
+
+
+
14
15
16
17
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of the three mutants, the lack of reactivity to mutant 1 suggests that it may play a role in 
IgE binding in a large group of patient.   
 Two patients had IgE to bind to all of the recombinant proteins probed.  
Interestingly, one of these had a relatively high IgE reactivity, 40 KIU/ml, and the other 
was low at 7 KIU/ml.  This showed that both sera contained IgE specific for Pol d 4 
however, other antibodies specific for CCD and other venom allergens maybe more 
abundant in some patients than others.   
 The recombinant forms of Pol d 4 were probed for IgE binding with sera from 
three patients sensitized by American paper wasps (Table 10).  All three sera showed 
strong reactivity to American paper wasps venom and patients 1 and 2 showed strong 
reactivity to yellow jacket venom.  Patient 1 showed very little binding to the 
recombinant form of Pol d 4 and the three mutant forms, however IgE from this patient 
bound to whole venom and the native protease.  This suggests that patients may have IgE 
specific for a different allergen with in the venom and that the native protease isolation 
may contain contaminating allergens.  Sera from patients 2 and 3 had IgE that bound to 
all forms of the recombinant serine protease.  Patient 2 serum displayed strong IgE 
binding to the recombinant protease and the three mutants, as well as the native serine 
protease and the whole venom extract.  This type of binding may have been due to the 
carbohydrate present on the protein.  The presence of carbohydrate-specific IgE may 
account for the binding of IgE from Patient 3 to the recombinant forms of Pol d 4.  The 
densitometric analysis of the immunoblot data showed that patient 2 had the strongest 
binding.   
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Table 10:  The binding patterns of IgE from American sera to multiple recombinant 
forms of Pol d 4.  Three American patient sera are listed along with the binding of 
patient IgE to various forms of recombinant Pol d 4 IgE binding was assayed on E. coli 
expressed recombinant form of Pol d 4 (Pol d 4), three mutant forms of Pol d 4 (mutant 1, 
mutant 2, and mutant 4), whole venom extract, and native Pol d 4.  Negative IgE binding 
(-), marginal binding (+/-), binding (+), and strong binding (++) are indicated for each 
sera. 
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A1
A2
A3
-
+
+
Patient rPol d 4       Mutant 1        Mutant 2 Mutant 4 Whole              Native
Sera Venom          Protease
+
+
+
+
+
+
-
++
+
-
++
+
-
++
+
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Evaluation of IgE binding from European patient sera to the three mutated forms 
of Pol d 4 was performed by densitometric analysis.  Data showed that the lowest number 
of patients had IgE to bind to mutant 1.  Only 35% of the sera assayed bound mutant 1.  
An important epitope is defined as one that will bind IgE from at least 80% or more of 
the patients’ sera (Burks et al., 1997).  The amino acid changes in mutant 2 seem to have  
decreased the IgE binding by 65%, which indicates this epitope may be important for IgE 
binding to Pol d 4.  The determination of the importance of the epitope being investigated 
with mutant 2, and possibly mutants 1 and 3, requires the evaluation of a larger 
population of sera from patients that have been sensitized to European paper wasps.   
 The importance in post-translational carbohydrate IgE binding to recombinant Pol 
d 4 may be important in explaining the results reported in Winningham et al. (2003)  
Several pieces of data obtained during the identification of baculovirus expressed Pol d 4 
suggests that the recombinant protease may be glycosylated. However, the presence of 
carbohydrate has not been directly identified.  Immunoblot inhibition was performed to 
investigate if CCD specific epitopes may be present on recombinant Pol d 4. 
 Bromelain, a highly glycosylated set of proteins, were used as competitors for 
CCD specific IgE in the Immunoblot inhibition assays.  Commercial bromelain mainly 
consists of two cysteine proteases, stem bromelain and fruit bromelain.  The conditions 
used during the inhibition assays did not meet optimal pH or temperature for the 
activation of bromelain (Rowan et al., 1990)   However, it is still possible for the 
activation of a small percentage of the cysteine proteases, which may affect the binding 
IgE.  The recombinant serine protease from P. dominulus does not contain the cleavage 
sites for either the fruit or stem bromelain protease. However, the involvement of 
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activated bromelain, even small percentages, may affect proteins present within the sera.  
Cleavage of IgE may present as a decrease in protein binding.  Proteolysis of other 
proteins present could theoretically expose pseudo-epitopes, either carbohydrate or amino 
acid, resulting in false positive results.  
 During the immunoblot assay a visual decrease in IgE binding to recombinant Pol 
d 4 in the presence of the bromelain competitor.   This pattern of IgE binding could 
suggest the presence of post-translational carbohydrate specific IgE.  However, it was 
previously stated that this type of moiety has not been definitive identified.  The decrease 
in IgE binding in the presence of bromelain may have been a result of non-specific 
binding the bromelain proteases or the activation of the cysteine proteases. Further study 
has to be performed the effectively determine the role of IgE binding to the post-
translational carbohydrate.  Primarily, the presence and composition of carbohydrate on 
the recombinant protease has to be clarified and characterized.  Secondly, an inhibition 
assay with a competitor that does not have the capacity to disrupt the system would be 
important.  Engineered molecules, such as the BSA neoglycopeptide, produced by 
Wilson et al. (1998). This molecule allows the presence of the bromelain carbohydrate 
groups which are conjugated onto BSA removing the possible effects of the cysteine 
protease activity while maintaining the IgE epitopes.     
 American patient 2 had IgE that readily bound all mutant forms of Pol d 4.  The 
serine protease from the American Polistes is hypothesized to be related to that found in 
the Old World paper wasps.  It is probable that the difference between European and 
North American paper wasps is not in the active site between these molecules but in the 
framework or surface regions (Sanchez et al., 1995 and Winningham et al., 2003).  These 
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regions would be responsible for the generation of specific IgE.  The data from the 
American Polistes sensitized patient suggest that the serine protease from Old and New 
World paper wasp groups may share epitopes.   
 Knowledge of the specific interactions between allergens and IgE antibody will 
aid in our understanding of the complex series of events that occur during an allergic 
reaction.  Details about allergens will enable researchers to better identify and 
characterize epitopes.  In addition, the characterization of allergens and their epitopes will 
allow optimal treatment of patients by immunotherapy using insect venom extract.  
Identification of species group-specific epitopes will aid in the generation of molecules 
for immunotherapy that will be hypoallergenic and protective (Maglio et al., 2002).  
Characterization of these molecules will help determine which expression system is 
optimal for recombinant production and the important components that are required for 
proper conformation.  Epitope mapping will also allow the generation of artificial 
conjugate molecules for treatment which may lead to better and safer patient care for 
insect allergies.                                          
4.3 Characterization of the allergenic serine protease from P.  gallicus (Pol g 4) 
 Members of the order Hymenoptera are responsible for fatal immunological 
reactions to insect venom (Valentine, 1992).  Cross-reactivity between allergens in the 
venom of these insects is caused by protein homology.  It has been shown that sequence 
identity correlates with the relatedness between insect species (Hoffman, 1981, Hoffman 
and McDonald, 1982, Hoffman, 1985, and Hoffman, 1986).  Epitopes that define an 
allergen’s immunologic reactiveness typically are composed of amino acid residues.   
The serine protease found in P. gallicus is an important venom allergen and it binds a 
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similar amount of IgE as Pol d 4 (Sanchez, 1995 and Winningham et al., 2004). To gain a 
better understanding of the apparent relatedness of these molecules, we characterized the 
cDNA sequence of Pol g 4.   The Pol g 4 sequence shared high identity with Pol d 4. 
Analysis of the sequences showed that both molecules share the same active sites with 
little variation in the framework.  This supports the high cross-reactivity of IgE binding 
between the venom serine proteases of P. dominulus and P. gallicus.   
4.4 Conclusions 
 The presence of carbohydrate and amino acid specific-IgE epitopes on the 
allergenic serine protease (Pol d 4) isolated from venom of P. dominulus was 
investigated.  Eukaryotic expression of Pol d 4 had a higher molecular weight than 
predicted and a heterogeneous charge, suggesting that a post-translational modification 
may have affected the recombinant protein.  Expression of two constructs in a 
prokaryotic system yielded protein that corresponded with the calculated size of Pol d 4, 
however, the folding of this protein into proper conformation was not confirmed using 
the described protocols.  Allergenic epitopes were predicted and three were mutated to 
investigate IgE binding. 
 Immunoblots showed IgE from the majority of European and American patients 
bound recombinant Pol d 4, demonstrating that the expressed protein had the ability to be 
immunologically reactive.  Further, assays with the same sera showed that IgE binding to 
the three mutants decreased by approximately half and this may indicate that these 
epitopes may be important in IgE binding in some patients.  Inhibition immunoblot 
studies showed a decrease in IgE binding, however, further investigation of the post-
 158 
translational modifications of recombinant Pol d 4 needs to be more extensive to 
determine if carbohydrate are definitively involved. 
 The molecular identification of the allergenic serine protease isolated from the 
venom of P. gallicus (Pol g 4) showed high identity with Pol d 4, followed by a variety of 
other insect serine proteases including, the honey bee and bumble bee venom serine 
proteases.  Comparison of the models generated with the sequences of Pol d 4 and Pol g 4 
showed structural similarities, suggesting both molecules may share allergenic epitopes.  
Additional studies of the allergenic serine protease from European and North American 
paper wasps are needed to fully understand the allergenic serine proteases’ role in the 
allergenic patient response.    
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